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ABSTRACT
THE SURVIVAL AND TREATMENT REFUSAL OF LUNG CANCER
PATIENTS: ANALYSES OF NATIONAL CANCER REGISTRIES
Poppy E. Deviany
University of Nebraska, 2018

Supervisor: KM. Monirul Islam, MD, MPH, PhD
Lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer
mortality of both genders in the United States. A recent report suggests that the relative five-year
survival rate of lung cancer is only 18%. Studies indicate many factors are associated with the
survival of lung cancer patients, including age at diagnosis. It is widely known as a disease of
older people, but the literature shows a substantial number of young people have been diagnosed
with lung cancer. The literature also indicates that the refusal of recommended treatment
contributes to cancer-related death and poorer survival. The objectives of this dissertation were to
estimate the survival of lung cancer patients, examine the effect of treatment refusal on survival,
and investigate factors associated with treatment refusal. To address these objectives, we
conducted our analyses using two large cancer databases: the Veterans Affairs Central Cancer
Registry and the National Cancer Database. We performed statistical data analyses using logistic
regression, the Kaplan–Meier survival estimator, and Cox regression (proportional hazards
regression) method. The results indicate a better five-year survival among younger-onset patients
compared with older-onset patients, particularly among early-stage cancer. In the multivariable
analyses, treatment refusal was associated with higher mortality risk. Furthermore, our results
suggested that patients of older age at diagnosis, female gender, with comorbid conditions, and
uninsured status were more likely to refuse recommended lung cancer treatment. In this
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dissertation, we could not analyze other relevant factors, such as types of comorbidity, patient’s
performance status, treatment side effects, family history of lung cancer, and cost of treatment,
due to data limitation. Adjusting such factors in future studies will provide a more robust
comparison of survival and genetic differences between younger- and older-onset lung cancer
cases. Future studies should also examine patients’ and clinical aspects of cancer education and
patient–physician communication materials to improve patient acceptance of lung cancer
treatment.
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CHAPTER 1
INTRODUCTION

Lung Cancer
Lung cancer begins with an abnormal growth of cells of the lung. The disease develops
following a series of pathological changes in the respiratory epithelium.1 In theory, lung cancer
grows from a single malignant cell into a detectable lesion.2 At the time of diagnosis, the majority
of the lung cancer patients are symptomatic. The most common initial symptom is a cough,
especially if the cancer grows in the central air-way.1,2 When the cancer is located in the
peripheral part, however, the cough may manifest as a late symptom. Other symptoms include
bronchorrhea, fever, chills, purulent sputum production, dyspnea, chest pain, hemoptysis, wheeze,
and stridor.3 The literature suggests that the local tumor growth, regional extension, metastases,
and a combination of mechanisms causes tumor-associated symptoms.3

Epidemiology of Lung Cancer
Globally, lung cancer has had a significant impact on morbidity and mortality for
decades. The disease has been reported as the most common cancer diagnosed worldwide since
1985.4 The GLOBOCAN report by the International Agency for Research on Cancer (IARC) in
2002 indicated that lung cancer accounted for 12% (1.35 million people) of all invasive cancers
diagnosed worldwide.4 A decade later, the IARC report in 2012 on cancer status worldwide
suggested an increase in the incidence of lung cancer to 1.8 million cases.5 The last report also
shows that in 2012 lung cancer was responsible for one in five cancer-related deaths in the
world.5
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Changes in the tobacco epidemic are thought to have affected the global differences in
lung cancer rates and trends.6,7 In countries such as the United States (US) and the United
Kingdom, the tobacco epidemic peaked in the middle of the 20th century and the highest
incidence of lung cancer rates was reported around that period.6,8 Lung cancer incidence has
declined since the mid-2000s, particularly among men.8 The increase in lung cancer rates among
women is considered to be the reflection of the increased frequency of smoking among
women.5,9,10 In countries where the number of smokers continues to increase, such as China,
Indonesia, and countries in Africa, more cases of lung cancer are anticipated in the next few
decades.5,6
A recent report by the American Cancer Society (ACS) suggests that 234,030 new cases
of lung cancer will be diagnosed in 2018 in the US.11 The estimation indicates that lung cancer
contributes to one in seven cancer cases in the country. The report also points out that lung
cancer-related deaths account for about 25% of all cancer mortality of both sexes.11,12
Advancements in lung cancer care, such as the use of low-dose spiral computed tomography for
screening and cancer-targeted therapy based on specific tumor molecular characteristics for a
treatment option, have contributed to some reduction in disease morbidity and mortality.5,11,13
However, lung cancer survival remains poor. The estimation made for the five-year relative
survival of lung cancer cases in the US in 2018 is 18%.12 The survival rate varies between early
and advanced stages; the five-year survival of local and distant stages were 56% and 5%,
respectively.12 Many epidemiologic studies have suggested that multiple factors affect lung
cancer mortality, including, patient characteristics, demographic, tumor clinical, geographic,
environmental, and therapeutic factors.8,14,15
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Risk Factors of Lung Cancer
A number of risk factors have been associated with lung cancer. Tobacco smoking has
been reported as the main risk factor.16,17 Other risk factors, such as environmental exposures,
family history of lung cancer, infection, and other substances exposures, have also suggested an
increased risk of lung cancer.14,16,17 In addition, the shift in smoking patterns has affected
individual susceptibility to lung cancer. Evidence of changes in patient characteristics, such as
age and gender, associated with the tobacco epidemic has been reported.17,18 Details on the
association of those risk factors and lung cancer are described in the following sections.
Cigarette Smoking
Tobacco mainstream smoke contains a mixture of approximately 4,000 compounds. Of
those compounds, studies have reported 60–70 carcinogens, such as polycyclic aromatic
hydrocarbons (PAHs), heterocyclic hydrocarbons, N-nitrosamines, and N-heterocyclic
amines.19,20 Lung cancer involves interactions between carcinogens and lung tissue. For example,
the incomplete combustion of tobacco during smoking will produce PAHs, and lung tissue
metabolizes these components to form mutagenic DNA adducts.2,21 The DNA adduct formation in
lung tissue is considered the initiating phase of carcinogenesis that leads to lung cancer.21,22 The
risk of lung cancer among smokers was estimated as 20 times higher than never-smokers.16
Furthermore, findings from case-control and cohort studies summarized in a paper by Alberg et
al. indicate the risk of lung cancer increases with the duration of smoking and number of
cigarettes smoked per day.23
Tobacco smoking is associated with more than 80% of lung cancer cases in the US.16,17 In
studies summarized by Cruz et al., four out of five adult smokers begin to smoke before the age
of 18 years in the US.17 The chronological trend suggests the average time lag between smoking
initiation and lung cancer occurrence is approximately 20 years.16,24 Considering the age of
smoking initiation and the time lag for tobacco to cause lung cancer, more smokers who started
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smoking as adolescents or young adults may be diagnosed with the disease at a younger age than
the current average age of lung cancer cases, that is 70 years. Nevertheless, the number of
cigarettes per day also affected this estimation.
Environmental Exposures
Occupational exposures have been reported as the second risk factor of lung cancer
following cigarette smoking, particularly in industrial countries.16 In many work settings, workers
are exposed to carcinogens, such as asbestos fiber, silica dust, metals including arsenic and
chromium, and radiation, which leads to an increased risk of lung cancer and other respiratory
diseases.5,23,25 Studies reviewed in an article by Alberg et al. indicate that asbestos exposure may
increase the risk of lung cancer to more than five times higher than non-exposure.16 The risk was
even higher among smokers due to the synergistic effect between smoking and asbestos
exposure.17,26
Similarly, an increased risk of lung cancer has been suggested due to exposure to high
linear energy transfer, such as radon, which was frequently reported among uranium miners.16,25
Studies reviewed in lung cancer literature suggest that approximately 9–15% of lung cancer cases
were associated with radon exposure.2,16 Radon, a natural soil-derived gas, is also found in
residential settings, and its presence may be increasing due to the low ventilation rates in indoor
air. A lack of association between indoor radon exposure and lung cancer was suggested by the
World Health Organization (WHO) at an exposure level of less than 100 Bq/m3, whereas the
recommendation from the Environmental Protection Agency for radon exposure in the US was
148 Bq/m3.27,28 Studies indicate a significant positive linear trend of radon concentration were
associated with the increasing risk of lung cancer.28-30 For example, a nonsmoker exposed to 200
Bq/m3 has a risk of developing lung cancer 1.5 times higher than those exposed to 100 Bq/m3; an
exposure of 400 Bq/m3 would result in three times higher risk.28 A synergistic effect on risk of
lung cancer was also suggested between smoking and radon exposure.16
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Family History of Lung Cancer
Individuals with a positive family history of lung cancer have a higher risk of lung
cancer,31,32 which may suggest the effect of both shared environmental factors and shared genetic
factors among family members. Individual factors, such as differences in carcinogen metabolism
and detoxification, DNA repair, cell cycle control, and inflammation pathways, have been
suggested to modify susceptibility to lung cancer.2 A meta-analysis of cohort and case-control
studies reported that positive family history of lung cancer increased individual risk of lung
cancer by 1.63 times; for those aged less than 50 years, the risk was even higher (odds ratio [OR]
= 2.08; 95% confidence interval [95% CI]: 1.18–3.63).31 Findings from other studies corroborate
the results of the association between positive family history of lung cancer and lung cancer
occurrence, particularly among the young.32-34 Cote et al. reported that a first-degree relative of a
lung cancer case had a 1.51 times higher risk of lung cancer after adjustment for smoking and
other covariates (95% CI: 1.39–1.63).35 The study also reported that the association was strongest
when the lung cancer case is a sibling (OR = 1.82; 95% CI: 1.62–2.05).35
Infection
Studies reviewed in a paper by Cruz et al. suggest that inflammation caused by
tuberculosis and tuberculosis-related scar contribute to lung cancer pathogenesis.17 In addition,
patients with HIV infection have been reported to experience a higher risk of lung cancer in
comparison to non-HIV infected individuals.16,36 As a potential explanation of this, Kirk et al.
reported a higher proportion of smoking among HIV infected people.37 This behavior combined
with an immunosuppressed condition increased the relative risk of lung cancer 3.6 times among
those with HIV infection as compared with those without HIV infection.36
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Other Substances
A cumulative exposure of carcinogens from ambient outdoor air pollution, such as
polycyclic aromatic hydrocarbon compound from fossil fuel, may cause inflammation in the
respiratory system.25 In urban or industrialized settings, a significant increase in lung cancer risk
has been reported due to increased fine particle concentration from engine emissions.38,39 Indoor
air contamination resulting from cooking combustion and space heating also has been reported by
studies, thereby increasing the risk of lung cancer.16,17
Age at Diagnosis
Diagnosis of lung cancer is common among individuals ages 65–74 years.12 Currently,
the median age at diagnosis of lung cancer in the US is 70 years.12 Data from 22 population-based
central cancer registries in the US over the period of 1995–1999 showed that lung cancer was
among the five most common cancers, with a significant increase in the younger age group,
particularly people aged 40–49 years.40 Population-based data has reported around 10% of cases
were diagnosed before age 55 years,12 while facility-based studies reported 12–14% of lung
cancer cases occurred before age 50 years.41-43 The literature suggests that the changes to the
median age at diagnosis in lung cancer cases of over 20 years earlier were associated with the
smoking epidemic among the young people.17,23,44
Previous studies that used the cutoff age at diagnosis as 40–50 years to define youngeronset cases reported differences in patient and tumor characteristics between younger- and olderonset patients. Those diagnosed at less than 50 years of age had higher proportions of advanced
stage at diagnosis,44-46 adenocarcinoma histologic subtype,47,48 and predisposing genetic
factors.33,49,50
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Gender
The association between gender and risk of lung cancer is closely related to cigarette
smoking.17,23 Although smoking prevalence was higher among men than women in the 1940s,18
after 1950 there was an increase in cigarette smoking among women, leading to the increased
incidence of lung cancer in women.17,18 Studies reviewed by Cruz et al. suggest gender
differences in the risk of lung cancer, indicating that a higher susceptibility among women may
be due to differences in nicotine metabolism, metabolic activation of lung carcinogens, and
hormonal factors between men and women.17

Diagnosis of Lung Cancer
Lung cancer evaluation aims to efficiently and accurately establish the diagnosis and
initial extent of the disease. The procedures include a check on medical history and physical
examinations, followed by imaging tests and tests to obtain tissue diagnosis and measurement on
the extent of disease.3
Smoking history, concurrent chronic obstructive pulmonary disease, and previous
exposures to certain environmental and occupational carcinogens are obtained from the patient as
part of individual medical history.3 In physical examinations, the patient’s general appearance
may be normal or may show signs, such as lethargy, pallor, jaundice, or other significant
comorbidities.3 Respiratory examinations may reveal issues with different areas. For example,
tachypnea (abnormally rapid breathing) may indicate pleural effusion, post-obstructive
pneumonia, or rib metastases; neck palpation may indicate that the cancer has spread to
supraclavicular lymph nodes; and bronchial breath sounds and increased fremitus indicate
consolidation with patent proximal airways.3
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The subsequent examination may utilize imaging procedures, including chest radiograph,
computed tomography (CT) and magnetic resonance imaging (MRI). Posteroanterior and lateral
chest radiograph is usually the first standard test to detect bronchogenic carcinoma.3,51 The
procedure also helps to assess the intrathoracic extent of the cancer, suggest subsequent work-up,
and identify other thoracic disease. The literature suggests a wide spectrum of findings from this
procedure, including a localized opacity (nodule or mass), pleural effusion, atelectasis,
adenopathy, and possible histologic type of lung cancer.3 A CT procedure has been suggested to
greatly enhance the imaging of bronchogenic carcinoma.17,51 The procedure can further define the
primary lesion’s appearance, detect simultaneous parenchymal or pleural disease, display
lymphangitic spread of malignancy, guide diagnostic maneuvers, and evaluate lymph nodes
metastases.3 In lung cancer evaluation, an MRI is not a routine procedure, although it can detect
vascular invasion better than a CT procedure.3
The accurate tissue diagnosis is important, not only to establish lung cancer diagnosis but
also to develop a treatment plan. In most patients suspected of lung cancer, biopsy procedures are
necessary because the clinical and radiographic procedures may not determine small cell lung
cancer (SCLC) and non-small cell lung cancer (NSCLC).3 The common techniques used to obtain
tissue for cytologic and histopathologic analysis are sputum examinations, flexible fiberoptic
bronchoscopy, transthoracic needle aspiration, endoscopic ultrasound, and thoracic surgery.3

Treatment of Lung Cancer
The treatment plan for lung cancer cases is defined mostly based on the type and stage of
cancer.13 The majority of recommendations are made for NSCLC and SCLC,13,24 which comprise
around 90–95% of total lung cancer cases.5,7,24
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Non-small Cell Lung Cancer
For early-stage cancer (stages I and II) that is operable, surgery and resection are utilized
as the primary treatment to provide increased longevity.24,52 A complete surgical resection,
including lobectomy or complete lymph node dissection, should be conducted, particularly when
smaller tumors (< 1–2cm) are identified.53 For patients with inoperable tumors, the options to
consider would include radiotherapy and/or chemotherapy.13,24,52 Durable results, including
reduction of toxicity and increase of five-year survival up to 40%, have been reported among
medically inoperable patients treated with advanced radiotherapy methods.53 Promising evidence
have been reported in the management of early-stage lung cancer, however, data from clinical
observations and cancer registries suggest that the majority (more than 70%) of lung cancer cases
are diagnosed at an advanced stage (stages III and IV).13
Lung cancer cases with operable stage III may receive multimodality therapy as a
standard treatment, such as surgery followed by chemotherapy.24,53 For inoperable stage III, the
treatment recommendation may include a sequential or concurrent combination of chemotherapy
and radiotherapy or external radiation alone.24,52 As cancer progresses to advanced stages, such as
stage IV, treatment options might include a combination of chemotherapy, palliative radiation,
and targeted therapy.13,52 Other factors, such as comorbidities, performance status, and genetic
factors, are considered for treatment recommendations.53
Small Cell Lung Cancer
Although small percentages of lung cancer cases are classified as SCLC (13–15%), the
disease has specific treatment recommendations as it is considered to be more aggressive and
often at wide dissemination at the time of diagnosis than NSCLC.24,54 Treatment for SCLC is
defined according to disease stage, general health, and existing comorbidities.24,53 The most
common treatment option for limited-stage SCLC is a combination of chemotherapy and
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radiation or chemotherapy alone; for extensive stage SCLC, the treatment recommendation
includes the combination of chemotherapy regimens or chemotherapy alone.55,56

Staging of Lung Cancer
Cancer staging describes the occurrence or spread of cancer at diagnosis, which is
essential in the diagnosis process and development of the treatment plan for lung cancer patients.
Cancer staging may help clinicians to identify the appropriate treatment plan, understand disease
prognosis, evaluate treatment results, etc.13,24,25 The TNM system is the standard International
Staging System for lung cancer administered by the Union for International Cancer Control.13,57
The T category defines the size and extent of the primary tumor, the N category defines the
absence or presence of regional lymph node involvement, and the M category defines the extent
of distant metastases.13,24 The tumor stage system used in cancer registries was based on TNM
staging in defining the categories of local stage (cancer confined to the organ of origin), regional
stage (cancer spread to nearby tissues or lymph nodes in the area of the organ of origin), and
distant stage (cancer spread to distant organs or parts of the body).11,13,57
In clinical practice and specific cancer registry, the TNM subsets with similar prognosis
and treatment option are combined into different stage groups. For NSCLC, the assigned stages
are 0, I, II, III, or IV; stage 0 is described as an in situ stage and the following stages are invasive
cancer.13,24,25 Stage I represents the early-stage invasive cancer, while stage IV represents the
most advanced stage. For SCLC, the combined staging group as applied in NSCLC is considered
irrelevant. The International Association for the Study of Lung Cancer (IASLC) recommends
different grouping of TNM staging system for SCLC by combining stages I–III into limited stage
(LS) and renaming stage IV as the extensive stage (ES).56,58 The limited stage (LS-SCLC) is
defined as cancer confined to the hemithorax of origin, the mediastinum, or supraclavicular
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lymph nodes, while the extensive stage (ES-SCLC) is defined as cancer that has spread beyond
the supraclavicular areas.24,56,58

Figure 1. 1 The Schematic Illustration of Non-Small Cell Lung Cancer Staging.
Originally presented in Lemjabbar-Alaoui H, et al. (2015). “Lung cancer: Biology and treatment
options.” Biochim Biophys Acta. 2015;1856(2):189-210.24 Reprinted with permission.

Histopathology of Lung Cancer
The international standard for histologic classification of lung tumors proposed by the
WHO and the IASLC includes major histologic types of lung cancer, such as adenocarcinomas,
squamous cell carcinomas, large cell carcinomas, and small cell carcinomas (SCLC).59 These
major types can be classified into many other subtypes based on the different clinical significance
of the tumor.59,60 The two most common histologic types are non-small cell lung cancer (NSCLC)
and SCLC; their proportions of all lung cancer cases are approximately 80–83% and 10–13%,
respectively.11,12 Studies suggest these histologic types have differences in etiology, pathology,
clinical features, and clinical management.24,59
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Of the NSCLC, adenocarcinoma accounts for approximately 40–45%12,61 and is
commonly found in peripheral parts of the lung.16,24 Adenocarcinoma occurs mainly in current or
former smokers, but is also the most common type of lung cancer seen in nonsmokers.62,63 In
addition, adenocarcinomas are more likely to occur in younger people than other types of lung
cancer.31,49 The second most common histologic type of NSCLC is squamous cell carcinomas,
which accounts for 25–30% of cases.12,61 This subtype is often linked to a history of smoking and
tends to be found in the central part of the lungs, near a major airway (bronchus).23,64,65
The SCLC tends to arise in the central mediastinum of the lung.56 Compared with
NSCLC, the SCLC is extremely aggressive and spreads rapidly to nearby tissues or lymph nodes
in the area of the organ of origin and is strongly associated with tobacco smoking.24,55,66 The
SCLC is a malignant epithelial tumor consisting of small cells with scant cytoplasm, ill-defined
cell borders, finely granular nuclear chromatin, and absent or inconspicuous nucleoli.67

Survival of Lung Cancer Patients
Analyses of lung cancer data from multiple countries indicate that lung cancer patients
had poor survivals; the five-year relative survival were 6–14% among men and 7–18% among
women.6 In developing and less developed countries the number was even lower; the five-year
relative survival of lung cancer cases was approximately around 9%.4,6 In the US, despite the
achievements in lung cancer care in previous years, improvements in the five-year survival of
lung cancer is low. A recent report indicates in four decades the absolute improvement of fiveyear relative survival of lung cancer was only 6.5%; the five-year relative survival reported in
1975 and 2012 were 12.2% and 18.7%, respectively.68
The low survival rate of lung cancer patients has been reported to be associated greatly
with an advanced cancer stage at diagnosis.6,68 Studies suggest that due to the nonspecific nature
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of lung cancer symptoms, the majority of lung cancer cases were diagnosed at advanced
stages,69,70 whereas available treatment options are most effective in early-stage cancer.13,25
Studies have suggested many other factors that affect the survival of lung cancer patients,
including patient characteristics such as age, gender, and race;41,71-73 smoking and smokingrelated comorbidities;74-77 treatment factors and socioeconomic factors.7,48,78-84
Tumor biology and hormonal factors were suggested in studies to explain gender-related
differences in the survival of lung cancer patients.73,85 The estrogen mechanism, capacity to repair
DNA damage, and PAH metabolism are some factors that differ between women and men.2 A
possible explanation for the effect of age is that young patients may have a better health condition
due to fewer comorbidities, which subsequently allows them to receive more aggressive treatment
and benefit the survival.41,45,46 However, studies also suggest that young lung cancer patients may
have a different character of disease that resulted in a worse prognosis. More of the young lung
cancer patients were diagnosed at an advanced stage; young lung cancer cases also were
suggested to have a different histologic type compared with older cases, which may indicate
genetic variation.45,48,86,87
The histologic type and stage of cancer may explain differences associated with
treatment. The NSCLC types of cancer are considered less aggressive,24 and with the available
treatment options the five-year relative survival of NSCLC was 23%; the survival of early-stage
cases was 60% and advanced stage cases was 5%.12 Whereas, for SCLC that has aggressive
growth and wide infiltration, a recent data suggest the five-year survival of SCLC cases was only
6.3%.12 The survival of SCLC has not significantly changed since the early 1990s.12 A metaanalysis study suggests that due to the toxicity associated with chemoradiation, the survival
benefit from treatment of LS-SCLC was limited to younger patients.88 Whereas findings from
other studies indicate a similar response to combined modality therapy were seen in older and
younger patients.89,90
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Treatment Refusal by Lung Cancer Patients
Patients with advanced chronic disease, such as lung cancer, are challenged with potential
trade-offs between treatment benefits and burdens. For example, a study by Fried et al. indicated
that for a low-burden treatment with restoration of current health, 98.7% of patients agreed to the
treatment; however, when the outcome was survival but at the same time having severe functional
impairment or cognitive impairment, more than 75% of patients decided to refuse the treatment.91
Rothman et al. suggested that high proportions of treatment refusal may indicate insufficient
patient-centered decision-making.92 Patients were more likely to refuse treatments that do not
meet their treatment goal, as also suggested in studies reviewed by Puts et al.93 Many factors
influence a patient’s decision to receive or forgo the recommended treatment. It may range from
individual factors (such as age, gender, and race) to culture, the burden of treatment (such as
length of hospital stay), extent of diagnostic procedures, invasive interventions, and the likelihood
of the outcome.91,94
A review of cancer studies by Ward et al. suggests that compared with other cancers,
lung cancer patients have higher rates of treatment refusal.95 The decline of recommended cancer
treatment was not only associated with poor survival but also higher mortality risk.63,96 In
addition, studies have suggested that age is one of the important factors that greatly influence a
cancer patient’s decision regarding treatment.94,97 Older lung cancer patients were more likely to
forgo treatment than their younger counterparts. Studies among early-stage NSCLC patients
reported a positive association between the increase of age and refusal of recommended surgical
treatment.98,99 However, due to data limitation, the studies were conducted only among earlystage lung cancer cases 98,99 or older lung cancer cases.98 Not including advanced stage in the
analysis of lung cancer is a disadvantage because majority of the cases diagnosed at advanced
stage.
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In terms of gender differences, studies reveal that women with lung cancer more likely
believed the disease to be incurable and that the treatment was only for comfort care.100,101 In
addition, limited access to cancer care due to lack of medical insurance is another factor
suggested by many studies to be associated with higher treatment refusal.95,102 Previous studies
indicate that the risk of being uninsured varies by age; young lung cancer patients were more
likely to be uninsured or underinsured as compared with their older counterparts 102,103

Limitations of Previous Research
Previous studies conducted to estimate the prognosis of lung cancer patients indicate that
many factors predict survival, including age at diagnosis. The inconclusive findings regarding
whether the diagnosis of lung cancer at a younger age benefits survival suggested the need to
examine the characteristics of younger-onset lung cancer cases and determine its difference with
older-onset cases, as well as investigate the survival of these groups. In addition, many studies
used simplify age category that was not represented younger-onset lung cancer.
Other studies have suggested that patient acceptance of recommended treatment is
another essential factor in survival and an important point to reduce lung cancer mortality.12,63,104
However, many of previous studies examined treatment refusal among early-stage cancer, or
limited their study population to those recommended for surgery in a single-site hospital, or
included small number of cases in the analysis. These restrictions may not allow a representative
estimate of treatment refusal among lung cancer cases because a higher proportion of lung cancer
diagnosed at advanced stages and more treatment refusal are anticipated from them.
In addition to gaps in the literature regarding survival of the young-onset lung cancer
patients, studies suggested many of the young lung cancer patients having issues with access to
cancer care.103,105,106 The Veterans Affairs Central Cancer Registry (VACCR) offers an
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opportunity to examine survival of patients who have similar access to cancer care and included
information such smoking history, family history, and chemotherapy, that are limited in other
databases.
To better describe the patient characteristics and have robust analyses, we used different
categories of age at diagnosis to address the younger-onset cases and included a larger sample of
lung cancer cases. Firstly, our analyses examined the characteristics of lung cancer patients
diagnosed at different categories of age and examined their survival. At the same time, we
investigated factors associated with survival, including age at diagnosis and treatment refusal.
Secondly, our analyses investigated factors associated with treatment refusal by patients. We used
two large cancer databases for our analyses; the National Cancer Database (NCDB), which
represents the general population, and the VACCR, which represents a unique veteran population.

Specific Aims
The burden of morbidity and mortality caused by lung cancer cases emphasize the urgent
need to conduct more studies to suggest improvement in cancer care. The overall objective of this
dissertation was to investigate survival and treatment refusal of lung cancer patients. We
established three specific aims to address the study objective.
Specific aim 1: To describe the characteristics and examine survival of NSCLC patients by
age at diagnosis
Specific aim 2: To investigate factors associated with treatment refusal and the impact of
treatment refusal on the survival of SCLC patients
Specific aim 3: To investigate factors associated with treatment refusal by NSCLC patients
These specific aims are presented as chapters 2–4 in this dissertation.
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Data Sources
National Cancer Database
The NCDB provides a clinical oncology database of hospital registry data collected from
more than 1,500 Commission on Cancer (CoC)-accredited facilities.107-109 The database included
cancer cases diagnosed and or treated at the CoC-accredited facilities. It supports data for national
cancer surveillance and resource for cancer quality improvement through a joint program of the
American College of Surgeons and the ACS.110 The database captures approximately 70% of
newly diagnosed cancer cases nationwide and more than 34 million records with detailed
information, including patient and tumor characteristics, treatments, and outcome.111,112
Veterans Affairs Central Cancer Registry
The VACCR serves a shared comprehensive cancer database of the US veterans
population from Veterans Affairs medical centers facilities.113,114 The Veteran Affairs provides an
integrated health care system access for veterans in a single payer system.114,115 The VACCR uses
standards established by institutions including the American College of Surgeons Commission on
Cancer, the American Joint Commission on Cancer, and the North American Association of
Central Cancer Registries, among others.113 Data in VACCR, include extensive demographics,
cancer identification, the extent of disease and staging, first course of treatment, and outcomes.113

Conceptual Framework
In this dissertation, we adapted the model on measures of patient-centered cancer
outcomes research using observational data by Carpenter et al.116 The model emphasizes the
expanding repositories of secondary data, such as cancer registry, and electronic health records,
and suggests the importance of presenting measures and outcomes in cancer care. Using the
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model as a baseline, we identified measures and outcomes from variables in cancer registries that
are relevant to our study objectives.
Figure 1.2 exhibits multiple factors relevant to factors associated with the survival of lung
cancer care. One important factor that we added in the model is treatment acceptance as
intermediate outcome. We view this model as a longitudinal process. For example, the
improvement in lung cancer care will eventually increase patient’s survival. However, prior to
evaluate the survival it is important to see the acceptance towards treatment.
Many of the variables listed in the model are not available for inclusion in our analyses;
however, it is helpful for future studies to include and adjust multiple factors, not only for cancer
care evaluation but also to address challenges in the interpretation of findings from previous
studies. Our analyses have included most components in the model, i.e., patient demographics
(age, gender, family history of cancer, race, category of residence, composite comorbidity,
primary payer/insurance status), provider characteristics (cancer care facility), cancer
characteristics (stage, histology), treatment (surgery, chemotherapy, radiation, and combined
therapies), intermediate outcome (treatment acceptance), and outcome (survival), these variables
are marked in the model. Taking into account various components in our analyses ensured the
reliability of our estimations and supported the interpretation of our findings.
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Figure 1. 2 Conceptual Model of the Survival of Lung Cancer Patients.
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CHAPTER 2
SURVIVAL OF NON-SMALL CELL LUNG CANCER PATIENTS
IN THE UNITED STATES VETERANS AFFAIRS POPULATION BY AGE

Abstract
Background: A significant number of young cases of non-small cell lung cancer (NSCLC) has
been reported. This study compared the characteristics of younger-onset cases to older
counterparts and examined their survival. Methods: We analyzed data from the Veterans Affairs
Central Cancer Registry (VACCR) from 2001–2008. We estimated survival probability using the
Kaplan–Meier method and compared survival of different age categories using Cox Proportional
Hazards regression analysis. Results: Of the 48,899 NSCLC cases studied, 1,182 patients were
diagnosed as younger-onset (< 50 years). The younger-onset group had high proportions of
advanced stage at diagnosis, current smokers, positive family history of cancer, and
adenocarcinoma histology. The five-year survival of younger-onset patients was 5.6% compared
with 3.0% of older-onset patients (> 70 years). Of those with early-stage (I and II), younger-onset
patients had a lower risk of mortality than intermediate-onset (50–70 years) (hazard ratio [HR] =
0.78; 95% CI: 0.62–0.98); the intermediate-onset patients had a lower risk than older-onset (HR =
0.66; 95% CI: 0.62–0.69). For advanced stage (III and IV), there was no difference in mortality
risk between younger- and intermediate-onset patients, whereas those with older-onset had a 24%
increased risk of mortality than intermediate-onset patients (HR = 1.24; 95% CI: 1.20-1.28).
Conclusions: Younger-onset NSCLC patients have a better five-year survival than older-onset
patients, although more of them were diagnosed at an advanced stage. Further investigations in
genetic or tumor molecular are recommended as younger-onset patients present with more
adenocarcinoma and positive family history than older counterparts.
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Introduction
In the US, lung cancer is the leading cause of cancer-related death, with an estimated
154,050 deaths in 2018.12 Of lung cancer subtypes, NSCLC accounts for 84% of the cases.12
Historically, lung cancer has been predominately diagnosed among the older population, with a
median age at diagnosis of 70 years. However, recent studies have reported a substantial
proportion of patients developed NSCLC at younger age.12,40,44,45
Patients with younger-onset NSCLC, age at diagnosis between 40 and 50 years, have
been reported to have distinct characteristics such as advanced stage at diagnosis,44-46 high
proportion of adenocarcinoma histologic subtype,47,48 and predisposing genetic factors33,49,50 in
comparison to older-onset patients. Previous studies have reported higher proportions of tobacco
use, a better performance status, and more aggressive treatment in younger-onset patients.41,45,46
These factors have been suggested as contributing factors for the different prognoses between
younger and older-onset NSCLC patients.
In previous studies, the influence of age at diagnosis on patient survival of NSCLC
patients has been found to be inconclusive. Studies conducted using different cancer registries,
i.e., Surveillance Epidemiology and End Results (SEER) and NCDB, have reported that young
patients tend to have less comorbidity and better performance status, which enable them to
receive more comprehensive treatment and results in better survival.45,47,79 Findings from a study
by Mauri et al. indicate no difference in overall survival between patients age < 45 and > 45
years.117 A hospital-based study by Bryant et al. indicated that younger NSCLC patients have a
significantly worse prognosis than older patients due to the aggressiveness of different cancer
types among the younger patients.48 Other than cancer aggressiveness, poorer survival among the
younger patients appeared to be related to limited access to and use of care among younger
patients. Insurance is a contributing factor related to issues in access to cancer care. Studies have
reported that more of younger-onset lung cancer patients did not have insurance and experienced
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delay in cancer diagnosis.103,105 Findings from studies also indicate that younger patients often
delayed visiting health care providers until they became symptomatic and thus were diagnosed at
a more advanced stage.42,43,48,86,118 Therefore, using a large cohort of patients, such as VA patients
who have similar access to cancer care, would allow the evaluation for effect of age at diagnosis
on patient survival.
The purpose of this study was to describe the characteristics of younger-onset NSCLC
cases and to examine the survival based on age at diagnosis of patients treated within the VA
health care system, which provides a more equitable access to health care.

Materials and Methods
Study Population, Design, and Data Source
The Veterans Affairs (VA) facilities maintain a shared comprehensive cancer database
that covers 132 Veterans Affairs medical centers. In addition, the VACCR contains demographic
and clinical information of cancer patients who have been diagnosed and/or treated at the VA
medical centers.113 The VACCR uses standards established by institutions including the
American College of Surgeons Commission on Cancer, the American Joint Commission on
Cancer, and the North American Association of Central Cancer Registries.113
In this retrospective cohort study, we analyzed data of patients with NSCLC of all
histology subtypes included in the VACCR database between 2001 and 2008. Analyses were
conducted utilizing data of those patients diagnosed with a primary invasive lung cancer with a
defined cancer stage at diagnosis (N = 48,899).
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Exposures and Outcomes
We included data on patient age at diagnosis, race, gender, smoking history, family
history of cancer, alcohol history, stage at diagnosis, histology type, and treatment received as
predictor variables. The five-year overall mortality, the study outcome, was defined as the time
from diagnosis of NSCLC to (a) the date of death (from any cause), (b) loss to follow-up, or (c)
vital status up to 60 months (after diagnosis), whichever came first. Age at diagnosis of NSCLC
was categorized as younger-onset (diagnosed before age 50 years), intermediate-onset (diagnosed
at age 50–70 years), and older-onset (diagnosed at 70 years and after).
Statistical Analysis
We used the chi-square test to compare patient characteristics, the Kaplan–Meier method
to estimate survival probabilities, and the log-rank test to assess survival differences.
Multivariable Cox Proportional Hazards (PH) regression was performed to examine the
association between age at diagnosis and overall survival, adjusting for other factors including
smoking history, alcohol history, family history of cancer, clinical stage, and histology subtypes.
The assumption of proportional hazards was tested using the log–log plots. Covariates with pvalue > 0.25 were excluded in the final model. All data were analyzed using the SAS software
version 9.4 (SAS Institute; Cary, NC).
Confidentiality and Ethics
The study used data from a de-identified VACCR database and was approved by the
Institutional Review Board at the VA-Nebraska Western Iowa Health Care System. The views
expressed in this publication are solely those of the authors, including the statements made in the
discussion and conclusions drawn from the data. The VA has not verified, and is not responsible
for, the analytic and/or statistical methods used in this study.
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Results
Demographic and Clinical Characteristics
Analyses included 48,899 NSCLC cases recorded in the VA database between 2001 and
2008. Of these 1,182 patients were diagnosed as younger-onset lung cancer. Comparison of
patient demographic and clinical characteristics by age categories are presented in Table 2.1.
Younger-onset patients were more likely to be diagnosed at an advanced stage (stages III
and IV) than the older groups. A higher proportion of adenocarcinoma was present among the
younger-onset patients, whereas more squamous cell carcinoma was observed among the olderonset patients. Higher proportions of younger-onset patients received combined cancer treatment
than either of the intermediate-onset and older-onset patients.
We used family history of cancer as a surrogate of inherent factors for lung cancer in our
analyses. A higher proportion of younger-onset patients had a positive family history of cancer
(39%) than older-onset patients (30%). The proportion of current smokers was higher among the
younger-onset patients (76%) in comparison to the intermediate-onset (62%), and older-onset
patients (37%) as shown in Table 2.1.
The Survival of NSCLC Cases
The younger-onset cohort had better median survival than older-onset patients (9 versus 7
months) as shown in Table 2.2. The five-year survival of patients diagnosed at the three age
categories was significantly different (log-rank p < 0.001). A higher proportion of younger-onset
patients (6%) survived to 60 months after diagnosis than intermediate-onset (5%) and older-onset
(3%) patients.
The log–log tests indicated all predictors met the proportional hazards (PH) assumption.
Therefore, we included age at diagnosis, smoking history, alcohol history, family history of
cancer, clinical stage at diagnosis, and histology subtype in multivariable analyses. Results were
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stratified by stage in Table 2.3 and indicated that among early-stage (stages I and II), youngeronset patients had a 22% lower risk of mortality than intermediate-onset patients (HR = 0.78;
95% CI: 0.62–0.98). No difference was found in the comparison of mortality risk between
younger-onset and intermediate-onset patients among those with advanced stage; however, olderonset patients had a 24% (HR = 1.24; 95% CI: 1.20–1.28) increased risk of mortality than
intermediate-onset patients.

Discussion
Our study results show that in the veteran population with NSCLC, overall survival is
affected by various factors, including age at diagnosis, smoking history, alcohol history, family
history of cancer, clinical stage at diagnosis, and histology. Of these factors, age at diagnosis and
cancer stage are factors that strongly influence patient survival. Younger-onset NSCLC patients
had a better five-year survival than patients diagnosed at an older age. Mortality risk stratified by
cancer stage showed consistent patterns. The younger-onset lung cancer patients had a lower
mortality risk than intermediate-onset, particularly among early-stage. Similarly, intermediateonset patients also showed a lower risk of death than those with older-onset in both early and
advanced stages of NSCLC.
As lung cancer has been widely regarded as a disease affecting older people, it is likely
that younger people may pay less attention to respiratory symptoms and may not think that they
could have developed NSCLC at a younger than typical age. In fact, some studies have suggested
that younger people’s decreased attention to their health leads to lower proportions of cancer
screening, causing them to be symptomatic at the time of presentation.41,119 Our findings were
corroborated previous studies that observed more of the younger-onset patient diagnosed with
NSCLC at stages III and IV.47,48 Moreover, Bryant et al. suggested that clinically NSCLC appears
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more aggressive among the young, which may be another reason the younger-onset group is
frequently found at a more advanced stage.48
Overall survival of patients diagnosed at different age categories in the multivariable
analyses showed that younger-onset patients had a lower risk of mortality than the older patients.
Similar findings have been reported by previous studies suggesting lower mortality risk among
younger-onset across cancer stages at diagnosis.45,47,79 One posited explanation of this has been
that younger-onset patients may have fewer comorbidities and are more likely to receive
aggressive treatment than older counterparts.41,46,71 Our analyses indicated that among the
veterans population, that received equal access to health care, those with younger-onset had less
mortality risk compared with those diagnosed in older groups, particularly among early-stage.
One possible explanation is that the disease aggressiveness in advanced stages of NSCLC reduces
the observed survival benefits in those with younger-onset.
An interesting finding in our analysis was the higher proportion of adenocarcinoma in
younger patients, despite the high proportion of current smokers. Of all histologic subtypes,
adenocarcinoma seems to have the least association with smoking, and is the most common
subtype of lung cancer in never and light smokers.63 Given the high proportion of a family history
of cancer in the younger-onset cohort, it is likely that in a setting of increased susceptibility, a less
cumulative smoking exposure may be needed to cause lung adenocarcinoma at a younger age.
Moreover, the possibility of other exposures among the veteran population, such as asbestos and
other chemicals components, could explain the increased risk of cancer among young adults.120
A strength of the present study was the ability to analyze smoking status among cancer
patients, a variable that is not available in most of the cancer registries such as SEER and NCDB.
In addition, the VA population has been known to have a higher proportion of smokers than the
general population.120,121 The increased proportion of NSCLC cases among the younger-onset
patients has been suggested by some researchers due to smoking “dose,” which is the number of
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cigarettes smoked, total pack-years, and age at smoking initiation.122 Our findings among the
veterans population were in agreement with previous studies42,43 and demonstrated a higher
proportion of current smokers among younger-onset patients. Bhat et al. suggested that current
smokers were more likely to be diagnosed with NSCLC at a younger age.62
Our results also demonstrated that a higher proportion of younger-onset patients had a
positive family history of cancer. This corroborates findings in other studies that have shown a
positive association between genetic and NSCLC, especially among the younger-onset
patients.32,35,49,50 It appears that inherited risk factors in combination with tobacco smoking
increases the risk of diagnosis with the disease at a younger age.33,49,50 Our study showed that the
median survival of patients with a positive family history of cancer was higher than those
without.
Other studies among NSCLC patients in the veterans population have suggested similar
findings, in that patients with a positive family history of cancer have a lower risk of mortality
than those without.62,123 This is possibly due to increased awareness among patients with a
positive family history, which leads to earlier lung cancer screening. In addition, because of
concern about military exposures and the accessible health care services provided by the VA
health care system, more veterans may be screened for lung cancer120 leading to earlier diagnosis
and receipt of prompt treatment resulting in better survival.
We have found no study addressed the issue of survival among different age at diagnosis
of NSCLC patients in the veteran population. The VACCR provided us with a large national
cancer database of veterans in the US, with equal access to care and comprehensive medical
insurance benefits available to all enrolled veterans.124 In addition, the database included
information on smoking history, family history of cancer, and treatment received including
chemotherapy, which is frequently stated as a limitation in previous studies using cancer registry
data.45,47 We believe that in comparison to previous cancer registry-based studies, our analyses
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demonstrate important findings on factors associated with survival of NSCLC patients,
particularly among younger-onset NSCLC patients in the US veterans population.
Nevertheless, we acknowledge the following limitations in our study. First, we were
unable to explain the variation in patient performance status and comorbidity on patient survival
as the database we utilized did not capture this information. A study by De Rijke et al. suggests
these two factors are important predictors of mortality and are correlated with increases in patient
age.125 Second, due to the characteristics of the veterans population, these findings may not be
generalizable to other cohorts. Studies have reported a higher proportion of female patients
among younger-onset,45,47,79 however, most of the patients in our study were male, thus we could
not explain variation according to gender. Nevertheless, it is unlikely that either of these factors
would have detracted the interpretation of the present study results.

Conclusions
Younger-onset NSCLC patients have a better five-year survival than older-onset patients.
The lower mortality risk observed in younger-onset NSCLC might indicate an area of
improvements such as better access to cancer screening and cancer care, and recommendations on
the use of aggressive treatments that will result in better patient survival. In addition, with more
younger-onset patients presenting with advanced stage cancer, adenocarcinoma, and positive
family history of cancer, further investigations into genetic or tumor molecular characteristics are
needed. These will help to understand the associations between genetic susceptibility,
environmental carcinogens including tobacco smoking, and treatment-specific factors on survival
of young NSCLC patients.
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Table 2. 1 Characteristics of Non-Small Cell Lung Cancer Patients by Age (N=48,899)
Characteristics
Gender
Female
Male
Race
White
Black
Others/unknown
Smoking History
Never smokers
Former smokers
Current smokers
Unknown
Alcohol History
Never
Former
Current
Unknown
Family History of Cancer
No
Yes
Unknown
Clinical Stage (AJCC)
I and II
III
IV
Histology
Adenocarcinoma
Squamous cell carcinoma
Large cell carcinoma
NSCLC, NOS
Others
Type of Treatment
Chemotherapy only
Radiation only
Surgery only
Chemoradiation
Surgery with chemotherapy with or
without radiation
No surgery or radiation or
chemotherapy recorded/
unknown

<50 years
(n = 1,182)
n
%

50–70 years
(n = 26,787)
n
%

>70 years
(n = 20,930)
n
%

p
value

101
1,081

8.54
91.46

528
26,259

1.97
98.03

240
20,690

1.15
98.85

< 0.001

779
371
32

65.91
31.39
2.71

21,478
4,702
607

80.18
17.55
2.27

17,168
3,304
458

82.03
15.79
2.19

< 0.001

40
149
893
100

3.38
12.61
75.55
8.46

659
7,618
16,635
1,857

2.46
28.44
62.17
6.93

907
10,438
7,754
1,831

4.33
49.87
37.05
8.75

< 0.001

223
239
540
180

18.87
20.22
45.69
15.23

6,244
6,296
10,015
4,232

23.31
23.50
37.39
15.80

6,619
4,916
5,283
4,112

31.62
23.49
25.24
19.65

< 0.001

413
460
309

34.94
38.92
26.14

9,727
9,960
7,100

36.31
37.18
26.51

8,210
6,249
6,471

39.23
29.86
30.92

< 0.001

283
358
541

23.94
30.29
45.77

7,965
7,426
11,396

29.73
27.72
42.54

6,902
5,790
8,238

32.98
27.66
39.36

< 0.001

456
290
53
282
101

38.58
24.53
4.48
23.86
8.54

8,927
8,877
870
5,766
2,347

33.33
33.14
3.25
21.53
8.76

5,784
7,248
518
4,284
3,096

27.63
34.63
2.47
20.47
14.79

< 0.001

160
167
170
347
128

13.54
14.13
14.38
29.36
10.83

3,662
4,170
4,840
5,628
2,135

13.67
15.57
18.07
21.01
7.97

2,278
4,101
3,244
2,210
679

10.88
19.59
15.50
10.56
3.24

210

17.77

6,352

23.71

8,418

40.22

NSCLC = non-small cell lung cancer; NOS = not otherwise specified

< 0.001
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Table 2. 2 Median Survival and Bivariable Analyses

Characteristics
Age

Gender
Race

Smoking History

Alcohol History

Family History of Cancer
Clinical Stage (AJCC)

Histology

Treatment

50–70 years
< 50
> 70
Female
Male
White
Black
Others/unknown
Never smokers
Former smokers
Current smokers
Never
Former
Current
No
Yes
I and II
III
IV
Squamous cell carcinoma
Adenocarcinoma
Large cell carcinoma
NSCLC, NOS
Others
No surgery or radiation or
chemotherapy
Chemotherapy only
Radiation only
Surgery only
Chemoradiation
Surgery with chemotherapy
with or without radiation

No. of
patient*

Median
survival
(month)

5-yr
survival
(%)

Logrank test
< 0.001

26,787
1,182
20,922
869
48,022
39,420
8,374
421
1,606
18,204
25,297
13,085
11,450
15,837
18,349
16,668
15,149
13,573
20,169
16,411
15,165
1,441
10,331
5,543
14,641

9
9
7
11
8
8
8
9
8
9
8
9
8
9
8
9
20
9
4
10
10
8
7
5
3

5.0
5.6
3.0
0.0
4.1
4.2
3.7
3.0
0.0
4.4
4.1
4.2
3.1
4.8
3.7
4.3
11.7
2.6
0.5
4.9
5.8
4.2
1.8
2.1
0.7

6,099
8,437
8,253
8,184
2,941

9
5
28
11
23

1.0
1.1
18.7
2.8
1.2

NSCLC = non-small cell lung cancer; NOS = not otherwise specified
*include number of patients with information on specific characteristics

< 0.001
0.546

< 0.001

< 0.001

< 0.001
< 0.001

< 0.001

< 0.001
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Table 2. 3 Multivariable Cox Regression of Factors Associated with Survival of NSCLC Cases
Stage I and II

Stage III and IV

Characteristics

Characteristics
AHR

Age
50–70 years
< 50
> 70
Smoking History
Never smokers
Former smokers
Current smokers
Alcohol History
Never
Former
Current
Family History
No
Yes
Clinical Stage
(AJCC)
I
II
Histology
Squamous cell
Adenocarcinoma
Large cell
NSCLC, NOS
Others
+

Ref
0.78
1.52
Ref
1.01
1.14

95% CI

0.62-0.98
1.44-1.61

0.88-1.17
0.99-1.31

p value

0.031
< 0.001

0.842
0.069

Ref
1.11
0.92

1.04-1.19
0.86-0.98

0.002
0.011

Ref
0.94

0.89-0.99

0.018

Ref
1.49
Ref
0.78
1.04
1.29
1.24

1.40-1.58

0.73-0.83
.88-1.23
1.20-1.39
1.13-1.36

< 0.001

< 0.001
0.614
< 0.001
< 0.001

Age
50–70
< 50
> 70
Smoking History
Never smokers
Former smokers
Current smokers
Alcohol History
Never
Former
Current
Family History
No
Yes
Clinical Stage
(AJCC)
III
IV
Histology
Squamous cell
Adenocarcinoma
Large cell
NSCLC, NOS
Others

Gender, race and treatment were not included in the multivariable analysis
AHR: Adjusted Hazard Ratio
CI: Confidence Interval

AHR

95% CI

p value

Ref
0.96
1.24

0.88-1.04
1.20-1.28

0.298
< 0.001

Ref
1.06
1.12

0.99-1.15
1.04-1.21

0.095
0.002

Ref
1.06
0.98

1.02-1.10
0.95-1.01

0.002
0.252

Ref
0.92

0.89-0.94

< 0.001

Ref
1.88

1.83-1.94

< 0.001

Ref
1.02
1.14
1.10
1.40

0.99-1.06
1.05-1.24
1.06-1.14
1.33-1.47

0.225
0.002
< 0.001
< 0.001
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CHAPTER 3
FACTORS ASSOCIATED WITH TREATMENT REFUSAL
AND IMPACT OF TREATMENT REFUSAL ON SURVIVAL OF
SMALL CELL LUNG CANCER PATIENTS

Abstract
Background: With less than 7% of small cell lung cancer (SCLC) patients surviving five years
after diagnosis, the receipt of recommended treatment is of utmost importance for patient
survival. Nevertheless, treatment refusal of SCLC patients has not been studied well. Our study
examined factors associated with treatment refusal and the effect of refusal on patient survival.
Methods: We analyzed data of 107,988 SCLC patients diagnosed between 2003 and 2012 from
the National Cancer Database. Treatment refusals were analyzed separately for
chemoradiotherapy among limited stage (LS-SCLC) and chemotherapy among extensive stage
(ES-SCLC) patients. We used logistic regression to investigate factors associated with treatment
refusal. We estimated survival probability using the Kaplan–Meier method and compared
survival of those who received and refused treatment using Cox Proportional Hazards regression
analysis. Results: The refusals of chemoradiotherapy among LS-SCLC and chemotherapy among
ES-SCLC patients were 1.34% and 4.70%, respectively. From 2003 to 2012, trends show an
increase of refusals, especially among the ES-SCLC recommended chemotherapy. Multivariable
analyses showed that in both SCLC groups, older age at diagnosis (> 70 years), female gender,
uninsured status, and presence of comorbidities were associated with treatment refusals. LSSCLC patients who refused chemoradiotherapy had a higher risk of mortality than those who
received treatment (hazard ratio [HR] = 4.96; 95% CI: 4.45–5.53); the median survival of those
who refused treatment was 3 months versus 18 months of those who received (p < 0.001).
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Similarly, ES-SCLC patients who refused chemotherapy had a higher risk of mortality than those
who received treatment (HR = 3.69; 95% CI: 3.48–3.92); the median survival was 1 month versus
7 months, respectively (p < 0.001). Conclusions: Treatment refusal among SCLC patients was
associated with worse survival; therefore, strategies to increase patient acceptance of the
recommended treatment need to be studied further.
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Introduction
Of the estimated 234,030 new lung cancer cases diagnosed in the United States (US) in
2018, more than 30,000 cases were identified as small cell lung cancer (SCLC).12 Analyses of the
surveillance, epidemiology, and end results reported the five-year survival rate of SCLC was less
than 7%.12 In addition, in the last two decades, the SCLC survival rate has shown little
improvement.83
Therapeutic options for SCLC have not significantly changed within the last 30
years.126,127 Concurrent chemoradiotherapy is typically recommended for patients diagnosed with
limited stage (LS-SCLC); whereas those diagnosed with extensive stage (ES-SCLC) are
predominantly treated with chemotherapy.55,126,128 Lack of patient acceptance of recommended
treatment has been implicated by previous studies as a key factor in SCLC survival.126,127,129
Nonetheless, there is a lack of research concerning treatment refusal among SCLC patients.127,130
Our study addressed this gap by examining factors associated with treatment refusal by
SCLC patients from a US national facility-based cancer registry. We also analyzed the trend of
treatment refusal over time as well as the effect of treatment refusal on patient survival.

Materials and Methods
Study Population, Design, and Data Source
The National Cancer Database (NCDB) provides national cancer surveillance data
through a joint program of the Commission on Cancer (CoC) of the American College of
Surgeons and the American Cancer Society (ACS).107 According to the United States Cancer
Statistics, this database captures approximately 70% of newly diagnosed cancer cases.107,112
We used cross-sectional design in the analysis of factors associated with treatment refusal
and retrospective cohort in the analysis of survival data. The sample for analysis were drew from
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the 198,405 SCLC cases diagnosed between 2003 and 2012. Figure 4.1 shows the sample
selection process. Criteria for data inclusion were: (1) confirmed diagnosis of primary invasive
SCLC according to the International Classification of Disease for Oncology Third Edition (ICDO-3) codes 8041-8045, (2) diagnosis established at a CoC-accredited facility and patient received
all or part of their treatment from CoC facility/facilities, (3) diagnosis confirmed with cancer
stage and patient treated at one or more of the following types of CoC facilities: community,
comprehensive community, and academic cancer programs, (4) known insurance status, and (5)
recommendation for first-course of treatment was either chemotherapy or radiation or
combination of chemoradiotherapy. We utilized the data of 107,988 eligible patients in our
analyses.
Exposures and Outcomes
We included sociodemographic and clinical characteristics as predictor variables.
Information on cancer stage was taken from the NCDB analytic stage, which uses standards
publicized by the American Joint Committee on Cancer (AJCC) 7th edition.107 In the analysis, we
followed the recommendation of the IASLC by grouping stages I–III as limited stage (LS-SCLC)
and stage IV as extensive stage (ES-SCLC).56 Comorbidity was recorded as Charlson/Deyo
Comorbid Conditions (CDCC).111 We used the NCDB definition of median income quartile
according to the proportion of income range in the patient’s area of residence for income
categories. The category of residence is based on information established by the United States
Department of Agriculture Economic Research Services.107
Our outcome variables were refusal of recommended treatment and five-year overall
mortality. Refusal of recommended treatment was defined as standard therapies recommended by
a physician(s) and refused by the patient. We analyzed data of those who were recommended
chemoradiotherapy among LS-SCLC and chemotherapy among ES-SCLC patients. Our analysis
focused particularly on treatment refusal by patients who were recommended the above therapies,
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through the comparison of their median survival to those who accepted recommended treatment.
In addition, we examined the effect of treatment refusal on patient survival in the multivariable
model.
Statistical Analysis
The chi-square test was used to examine differences in demographic and clinical
characteristics of patients with limited and extensive stages of SCLC who refused and received
the recommended treatment. We used multivariable logistic regression to examine factors
associated with refusal of chemoradiotherapy among patients with LS-SCLC and refusal of
chemotherapy among patients with ES-SCLC. Backward selection was used to fit the
multivariable logistic regression model. Changes in the proportion of treatment refusal over time
for cases diagnosed between 2003 and 2012 are shown graphically in Figure 4.2. We used the
Kaplan–Meier method to estimate survival probabilities and log-rank test to assess survival
differences. We performed multivariable Cox Proportional Hazards (PH) regression to examine
the effect of treatment refusal on the risk of mortality adjusted for other factors. The PH
assumption was tested using the log–log plots; all predictors met the proportionality assumption.
Analyses were performed using the SAS software version 9.4 (SAS Institute; Cary, NC).
Confidentiality and Ethics
We used data from a de-identified NCDB file. The ACS and CoC have not verified, and
neither is responsible for the analytic and statistical methods utilized in this study. The statements
made in the discussion and the conclusions drawn from these data are solely the authors’
responsibility. This study has been classified as exempt by University of Nebraska Medical
Center’s Institutional Review Board due to the use of de-identified data.
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Results
Demographic and Clinical Characteristics
Of the 107,988 SCLC cases included in the analysis, 40,432 cases were diagnosed with
LS-SCLC and 67,556 cases with ES-SCLC. Comparison of characteristics of patients who
received and refused treatment for LS-SCLC and ES-SCLC are presented in Table 3.1. Separate
analyses among those LS-SCLC and ES-SCLC showed that a higher proportion of patients of
older-onset age (> 70 years), female and treated at the comprehensive community cancer program
refused the recommended treatment modalities (p < 0.001). Interestingly, those without
comorbidity had a higher proportion of refusal than those with comorbidities.
For the first-course treatment (data not shown), of the LS-SCLC patients (n = 40,432)
recommendation for chemoradiotherapy was given to 75% of the cases. Among patients
diagnosed with ES-SCLC (n = 67,556), the majority of them were recommended either for
chemotherapy (47%) or chemoradiotherapy (45%).
The Trend of Treatment Refusal
In total, 1,898 cases declined the recommended chemoradiotherapy of LS-SCLC and the
recommended chemotherapy of ES-SCLC. Figure 4.2 shows an increase in the proportion of
refusal of each therapy over 10 years. Overall, refusal of the recommended chemoradiotherapy
among patients diagnosed with LS-SCLC was 1.34% and refusal of the recommended
chemotherapy among ES-SCLC patients was 4.7%. Analysis of 10 years’ worth of data shows
that the increase in refusal among those with ES-SCLC was higher (50%) than it was among
those with LS-SCLC (34%).
Factors Associated with Treatment Refusal
After adjusting for demographic and clinical characteristics, we found that age at
diagnosis, gender, insurance status, and comorbidity score were associated with the refusal of
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chemoradiotherapy among LS-SCLC patients (Table 3.2). Patients diagnosed at age > 70 years
were more likely to refuse treatment than those aged 50–70 years; the adjusted odds ratio (AOR)
for refusal of chemoradiotherapy was 3.50 (95% CI: 2.77–4.44). Women were more likely to
refuse recommended chemoradiotherapy than men, AOR was 1.29 (95% CI: 1.05–1.58).
Compared with those with private insurance, uninsured patients were more likely to refuse
treatment (AOR = 3.61, 95% CI: 2.05–6.35). In addition, we found that patients with comorbid
conditions were more likely to refuse recommended chemoradiotherapy than those without
comorbidity, AOR was 2.54 (95% CI: 1.94–3.31).
The multivariable logistic regression analysis showed that similar factors, as those
observed in the analysis of LS-SCLC, were associated with refusal of chemotherapy among ESSCLC patients (Table 3.2). Patients diagnosed at age > 70 years were more likely to refuse
chemotherapy than those age 50–70 years (AOR = 2.25; 95% CI: 1.99–2.55). Women were more
likely to refuse recommended treatment than men (AOR = 1.42; 95% CI: 1.27–1.58). Uninsured
patients were more likely to refuse chemotherapy than those with private insurance (AOR = 1.76;
95% CI: 1.29–2.40). ES-SCLC patients with comorbidities were more likely to refuse
chemotherapy than patients without comorbidity, AOR was 1.43 (95% CI: 1.23–1.65). As
previous studies had suggested,131,132 interactions of race with variables including gender,
insurance status, and comorbidity were examined separately for both LS-SCLC and ES-SCLC,
but no significant association was found.
The Survival of SCLC Cases
The overall median survival for all SCLC patients included in the analysis was 9.4
months. Among LS-SCLC patients who were recommended chemoradiotherapy, the median
survival of patients who refused and received the treatment were 3 and 18 months, respectively (p
< 0.001) (Figure 4.3). For ES-SCLC patients, median survival of those who refused
chemotherapy was 1 month compared with 7.5 months of patients who received treatment (p <
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0.001). Within one year following the diagnosis (data not shown) among LS-SCLC patients who
were recommended chemoradiotherapy, 67% of patients who received the treatment had
survived, compared with 14% of those who declined. The five-year survival of LS-SCLC patients
who received chemoradiotherapy was 17% compared with only 2% of those who refused (Figure
4.3). For ES-SCLC, the one-year survival of patients who received the recommended
chemotherapy was 25%, compared with 3% of those who refused.
We included age, gender, primary payer, category of residence, presence of comorbidity,
facility, and treatment status in multivariable analyses using Cox PH regression. Results are
presented in Table 3.3 and indicate that among LS-SCLC patients recommended
chemoradiotherapy, those who refused treatment had a higher risk of mortality than those who
received treatment (hazard ratio [HR] = 4.96; 95% CI: 4.45–5.53). Similarly, among ES-SCLC
patients who were recommended chemotherapy, patients who refused treatment had a higher risk
of mortality than those who received (HR = 3.69; 95% CI: 3.48–3.92).

Discussion
Our study found that the majority of first-course treatments received by SCLC patients in
the database met national clinical practice guidelines, which include a combination of
chemoradiotherapy for LS-SCLC and chemotherapy alone for ES-SCLC.55,133 Regarding survival
among both LS-SCLC and ES-SCLC groups, patients who accepted recommended treatment had
significantly higher survival than those who refused. The overall refusal of the recommended
chemoradiotherapy among LS-SCLC patients was 1.34% and refusal of chemotherapy among
ES-SCLC patients was 4.7%. These proportions are smaller than the overall treatment refusal
reported by Ward et al., which was 9% from analysis of 11 cancer sites.95 Our analyses indicated
that over time there were increases in the proportions of treatment refusal of both LS and ESSCLC patients. This was particularly so among ES-SCLC patients, where the refusal of treatment
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increased by 50% in 10 years. The fact that three-fourths of SCLC cases are diagnosed with ESSCLC suggests that our findings on treatment refusal deserve special attention. Aizer et al.
indicate that compared with other cancers, refusal of treatment among SCLC patients was more
likely to result in death due to cancer.63
Of factors associated with treatment refusal, age at diagnosis was significantly associated
with refusal of both chemoradiotherapy for LS-SCLC and chemotherapy for ES-SCLC. After
adjusting for other characteristics, patients diagnosed at a younger age were less likely to refuse
treatment compared with older patients. A meta-analysis among LS-SCLC suggested that due to
the toxicity associated with chemoradiotherapy, the survival benefit from treatment was limited to
younger patients.88
However, other studies have shown that both older and younger patients respond just as
well to a combined modality therapy.89,90 A recent study using NCDB data suggested that older
patients who received combined modality therapy had a better overall survival than for
chemotherapy alone.134 Younger patients are considered to have better performance status, less
comorbid conditions, and increased life expectancy, which are all factors that support the decision
to agree to cancer treatment.135 Older patients, on the other hand, have increased concerns
regarding the tolerability of chemotherapy, treatment duration and effectiveness, as well as
comorbid conditions that affect the decision to decline the offered treatment.93,135 Analyses of the
population and facility-based data in previous studies have shown a continuous increase in the
proportion of SCLC patients diagnosed who were over the age of 70 years.136-138 If more SCLC
patients are diagnosed at an older age, it may be reasonable to expect that the proportion of
treatment refusal will continue to rise, due in part to the aforementioned array of concerns of
older patients.
Regarding association with gender, previous studies have suggested an increased
incidence of SCLC cases among women.139,140 Women with SCLC were also shown to have
better survival than men,128,139 with gender differences in survival being linked to patients’
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perceptions of cancer care.100,101 A recent study by Lee et al. showed that more women did not
receive active cancer therapy (no treatment) for their initial treatment modality of SCLC.141 These
findings are in agreement with our results, which suggested that women were more likely to
refuse the recommended chemoradiotherapy for LS-SCLC and chemotherapy for ES-SCLC.
Refusal linked to gender may occur because women with advanced cancer tend to value the
quality of life more than just prolonging life.142 As also indicated in other cancer studies, women
seemed to be more vulnerable to treatment toxicities than men, and were more likely than men to
plan for other things in their end-of-life rather than repeatedly visiting medical facilities to
complete cancer treatment series.100,143 These perceptions may affect women’s decisions to
decline recommended cancer treatment. Our findings suggest the need for future studies to
investigate the perception of SCLC treatment and expectations regarding their cancer treatment
among women.
Uninsured patients were 2–3 times more likely to decline chemoradiotherapy for LSSCLC and to decline chemotherapy for ES-SCLC than those with private insurance. Other studies
among lung cancer cases have been suggested that uninsured patients were more likely to refuse
the offered cancer treatment.103,144 In addition, Halpern et al. also suggested that the uninsured
were more likely to be diagnosed with advanced stage disease.103 The American Society of
Clinical Oncology has raised concerns about inequities in cancer care due to insurance status.145
A study by Duh et al. estimated that the average cost of IV chemotherapy for SCLC was $788 per
visit or $9,449 per treatment course (three visits per cycle for four cycles).146 For uninsured
patients, these costs may affect their decision to accept or decline recommended cancer treatment.
Furthermore, any factor that delays treatment, could result in a more advanced and aggressive
disease. To ensure delivery of quality cancer treatment and optimize patient outcomes, it is
important to identify and remove impediments related to the health payer.
Results of survival analysis in this study demonstrate that the one-year survival of LSSCLC patients who received chemoradiotherapy was five times higher than those who refused.
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Among ES-SCLC, those who received chemotherapy were eight times more likely to survive for
one year compared with those who refused recommended treatment. Similar to our study, Lally et
al. and Behera et al. have previously suggested better survival rates among SCLC patients who
received treatment than those who did not.136,147 Regardless of the benefit on survival of receiving
treatment, patient autonomy and locus of control remain important aspects of care. Patient–
provider communication and patient education are essential in decision-making to increase
patient acceptance of standard recommended treatment.
To our knowledge, our study is the most comprehensive one that has analyzed treatment
refusal among SCLC patients using a national facility-based database. We specifically examined
the treatment refusal of chemoradiotherapy for LS-SCLC and chemotherapy alone for ES-SCLC,
as these have the strongest evidence bases as stage-specific recommended treatments modalities
for SCLC patients. Our findings are relevant for patient management and future studies. The main
strengths of our study are in the use of comprehensive clinical information including cancer stage
and treatment recommendations, and a large sample size of SCLC cases included in our analyses.
We used the database that includes approximately three-fourths of newly diagnosed cancer in the
US population.107,112
The main limitations of our study are those seen with retrospective and database studies
in general. Although the database covers a majority of cancer cases in the US, around 20% of
newly diagnosed are not captured in the data.103 However, only marginal differences between
NCDB and the SEER data have been acknowledged and should not meaningfully affect our
findings.148 Our findings suggested the necessity for future studies to focus on factors that might
contribute to treatment decision, for example patient–physician interactions, patient education
regarding cancer treatment and care, and patient support networks.
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Conclusions
Although the proportion of patients refusing treatment for SCLC is relatively low, the
increase in the treatment refusal over time is concerning. Older age at diagnosis, female gender,
uninsured status, and comorbidities were associated with higher refusal of chemoradiotherapy
among LS-SCLC and higher refusal of chemotherapy among ES-SCLC patients. It is important
for health providers and policymakers to not only make good treatment recommendations but also
consider the ways their recommendations are delivered to patients. Interventions targeting factors
associated with higher treatment refusal may increase acceptance of recommended treatment and
ultimately improve patient survival.

44
Figure 3. 1 Sample Selection
Small cell lung cancer diagnosed between 2003–2012 in NCDB (N = 198,405)
Excluded from sample selection (n=46,528)+
-

Single or multiple cancer diagnoses and lung cancer was not the
primary cancer (n = 32,158)
Non-invasive lung tumor (n = 1)
Diagnosed but did not receive any treatment from the reporting CoC
facility (n = 17,400)

n = 151,877

Excluded from sample selection (n = 19,112)+
-

13,817 patients were not having a confirmed stage at diagnosis
186 Patients treated at “other” cancer programs
5,756 patient insurance status listed as other government or unknown

n = 132,765
Excluded from sample selection n = 24,777 because patients were not
recommended either chemotherapy or radiation or combination of
chemoradiotherapy as their first-course treatment for SCLC

Sample size for analysis (n = 107,988)

+

Criteria are non-mutually exclusive
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Figure 3. 2 Refusal of Recommended SCLC Treatment by Stage at Diagnosis, NCDB 2003–2012
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Figure 3. 3 Survival Plots of Chemoradiotherapy for LS-SCLC and Chemotherapy for ES-SCLC
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Table 3. 1 Characteristics of Small Cell Lung Cancer Cases Who Received and Refused
Treatment

Characteristics
Age at diagnosis (years)
< 50
50–70
> 70
Gender
Male
Female
Race
White
Black
Others/unknown
Median Income Quartiles
2008–2012
< $ 38,000
$ 38,000–$ 47,999
$ 48,000–$ 62,999
$ 63,000 +
Unknown
Category Residence
Metro counties
Urban counties
Rural counties
Unknown
Insurance status
Uninsured
Private insurance
Medicaid
Medicare
Charlson/Deyo Comorbid
Conditions (CDCC)
No comorbid condition
Score 1
Score 2

Limited Stage+ (n = 30,585)
Received
Refused
n = 29,001
n = 409
n (%)
n (%)

p value

Extensive Stage++ (n = 31,679)
Received
Refused
n = 29,792
n = 1,489
n (%)
n (%)

p value

2,280 (7.9)
18,950 (65.3)
7,771 (26.8)

8 (2.0)
142 (34.7)
259 (63.3)

< 0.001

1,736 (5.8)
17,886 (60.0)
10,170 (34.1)

34 (2.3)
573 (38.5)
882 (59.2)

< 0.001

12,816 (44.2)
16,185 (55.8)

156 (38.1)
253 (61.9)

0.014

15,566 (52.3)
14,226 (47.8)

651 (43.7)
838 (56.3)

< 0.001

25,972 (89.6)
2,370 (8.2)
659 (2.3)

362 (88.5)
34 (8.3)
13 (3.2)

0.470

27,047 (90.8)
2,034 (6.8)
711 (2.4)

1,358 (91.2)
92 (6.2)
39 (2.6)

0.542

6,290 (21.7)
8,116 (28.0)
7,510 (25.9)
6,298 (21.7)
787 (2.7)

100 (24.5)
118 (28.9)
100 (24.5)
88 (21.5)
3 (0.7)

0.101

6,188 (20.8)
7,924 (26.6)
7,784 (26.1)
6,899 (23.2)
997 (3.4)

317 (21.3)
398 (26.7)
402 (27.0)
330 (22.2)
42 (2.8)

0.664

21,633 (74.6)
5,428 (18.7)
723 (2.5)
1,217 (4.2)

310 (75.8)
81 (19.8)
9 (2.2)
9 (2.2)

0.228

22,293 (74.8)
5,275 (17.7)
781 (2.6)
1,443 (4.8)

1,119 (75.2)
264 (17.7)
43 (2.9)
63 (4.2)

0.681

1,262 (4.4)
10,661 (36.8)
2,416 (8.3)
14,662 (50.6)

17 (4.2)
46 (11.3)
24 (5.9)
322 (78.7)

< 0.001

1,436 (4.8)
9,056 (30.4)
2,421 (8.1)
16,879 (56.7)

57 (3.8)
222 (14.9)
75 (5.0)
1,135 (76.2)

< 0.001

18,058 (62.3)
7,974 (27.5)
2,969 (10.2)

169 (41.3)
154 (37.7)
86 (21.0)

< 0.001

16,269 (54.6)
9,193 (30.9)
4,330 (14.5)

664 (44.6)
530 (35.6)
295 (19.8)

< 0.001

CoC Facility
Community Cancer Program
4,323 (14.9)
75 (18.3)
0.036
4,438 (14.9)
218 (14.6)
0.002
Comprehensive Community
17,704 (61.1)
254 (62.1)
17,941 (60.2)
959 (64.4)
Cancer Program
Academic/Research Program
6,974 (24.1)
80 (19.6)
7,413 (24.9)
312 (21.0)
+ LS-SCLC patients who were recommended chemoradiotherapy, including those who did not receive for unknown reason
++ ES-SCLC patients who were recommended chemotherapy, including those who did not receive for unknown reason
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Table 3. 2 Multivariable Logistic Regression of Factors Associated with Refusal of Small Cell
Lung Cancer Treatment
Characteristics

AOR

95% CI

p value

Limited Stage – SCLC
Age at diagnosis
(years)
Gender
Primary Payer

CDCC

50–70
< 50
> 70
Male
Female
Private insurance
No insurance
Medicaid
Medicare
No comorbid
Score 1
Score 2

Ref
0.47
3.50
Ref
1.29
Ref
3.61
2.50
2.41
Ref
1.86
2.54

50–70
< 50
> 70
Male
Female
Private insurance
No insurance
Medicaid
Medicare
No comorbid
Score 1
Score 2

Ref
0.73
2.25
Ref
1.42
Ref
1.76
1.32
1.72
Ref
1.29
1.43

< 0.001
0.22–1.01
2.77–4.44
0.016
1.05–1.58
< 0.001
2.05–6.35
1.51–4.12
1.72–3.38
< 0.001
1.49–2.33
1.94–3.31

Extended Stage – SCLC
Age at diagnosis
(years)
Gender
Primary Payer

CDCC

< 0.001
0.51–1.04
1.99–2.55
< 0.001
1.27–1.58
< 0.001
1.29–2.40
1.01–1.74
1.46–2.02
< 0.001
1.15–1.46
1.23–1.65

AOR = Adjusted odds ratio
CI: Confidence interval
Note: In the final model variables race, category of residence, and facility were not significantly associated
with treatment refusal among LS-SCLC and ES-SCLC.
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Table 3. 3 Multivariable Cox Regression of Factors Associated with Survival of SCLC Cases
Characteristics

AHR

95% CI

p value

Limited Stage – SCLC+
Age at diagnosis
(years)
Gender
Primary Payer

CDCC

Facility

Combination of
chemoradiation

50–70
< 50
> 70
Male
Female
Private insurance
No insurance
Medicaid
Medicare
No comorbid
Score 1
Score 2
Community
Comprehensive
Community
Academic/Research
Received
Refused

Ref
0.91
1.27
Ref
0.82
Ref
1.17
1.20
1.18
Ref
1.18
1.36
Ref

50–70
< 50
> 70
Male
Female
White
Black
Others/unknown
Private insurance
No insurance
Medicaid
Medicare
No comorbid
Score 1
Score 2
Community
Comprehensive
Community
Academic/Research

Ref
0.95
1.17
Ref
0.85
Ref
0.93
0.95
Ref
1.17
1.11
1.12
Ref
1.16
1.41
Ref

< 0.001
0.86–0.97
1.23–1.32
< 0.001
0.79– 0.84
< 0.001
1.09–1.26
1.14–1.27
1.14–1.23
< 0.001
1.14–1.21
1.30–1.43
< 0.001

0.95

0.91–0.98

0.91
Ref
4.96

0.87–0.95
< 0.001
4.45–5.53

Extended Stage – SCLC++
Age at diagnosis
(years)
Gender
Race

Primary Payer

CDCC

Facility

< 0.001
0.90–1.00
1.13–1.20
< 0.001
0.83–0.87
0.012
0.89–0.98
0.87–1.03
< 0.001
1.10–1.25
1.06–1.17
1.09–1.16
< 0.001
1.13–1.20
1.36–1.47
0.005

1.01

0.98–1.05

0.96

0.93–1.00

50

Characteristics
Combination of
chemotherapy

Received
Refused

AHR
Ref
3.69

95% CI

p value
< 0.001

3.48–3.92

AHR = Adjusted hazard ratio
CI: Confidence interval
+ LS-SCLC patients who were recommended chemoradiotherapy
++ ES-SCLC patients who were recommended chemotherapy
Note: In the final model variables category of residence was not significantly associated with survival
among LS-SCLC and ES-SCLC.
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CHAPTER 4
FACTORS ASSOCIATED WITH REFUSAL OF RECOMMENDED
TREATMENT BY PATIENTS WITH NON-SMALL CELL LUNG CANCER:
AN ANALYSIS OF NATIONAL CANCER DATABASE 2003–2012

Abstract
Objectives: Refusal of recommended treatment contributes to a higher number of cancer-related
deaths. Our study aimed to analyze factors associated with treatment refusal among non-small
cell lung cancer (NSCLC) patients. Materials and Methods: We analyzed data on 884,817
NSCLC patients from the National Cancer Database diagnosed between 2003 and 2012. The
analysis of treatment refusal was carried out for surgery (stages I and II) and chemotherapy
(stages III and IV). Logistic regression was used to investigate factors associated with treatment
refusal. Results: Patients diagnosed at age < 50 years were less likely to refuse treatment than
those age 50–70 years; the adjusted odds ratio (AOR) of treatment refusal comparing these two
groups was 0.37 for surgery and 0.58 for chemotherapy. Compared with patients with private
insurance, uninsured patients were more likely to refuse surgery (AOR = 2.47) and chemotherapy
for stage III (AOR = 2.56) and IV (AOR = 2.50). Patients with comorbid conditions were less
likely to refuse surgery for stage I and II (AOR = 0.87) but more likely to refuse chemotherapy
for stage III (AOR = 1.94) and stage IV (AOR = 1.99). In comparison with those treated at
community facilities, patients treated at academic facilities were less likely to refuse surgery
(AOR = 0.45) and chemotherapy for stage III (AOR = 0.78), and stage IV (AOR = 0.68).
Conclusions: Multiple patient and system-related factors, such as older age at diagnosis,
comorbid conditions, and uninsured status, were associated with higher treatment refusal.
Consideration of these factors is essential in patient education and patient–provider
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communication to increase patient acceptance of the recommended treatment that may improve
patient outcomes.
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Introduction
An estimated 234,030 new cases of lung cancer will be diagnosed in the US in 2018.12
The disease is responsible for one in four cancer deaths; more than any other cancer in the US.12
Many studies have reported the underuse of treatment modalities recommended to cancer
patients, with lung cancer having higher treatment refusal rates in comparison to other
cancers.63,95,97 Refusal of recommended cancer treatment is a contributing factor to cancer-related
death and could be a potential cause for failure to achieve a significant reduction in lung cancer
mortality.12,63,104
Previous studies that used cancer registry data have provided important insights;
however, because of data limitations, they have not typically examined refusal of
chemotherapy.45,71,148 The exclusion of chemotherapy is problematic as it is currently considered
the most important treatment modality for advanced non-small cell lung cancer (NSCLC) and
forms an integral part of care for patients with early and locally advanced disease.24,149 Although
surgery provides an opportunity to cure nonmetastatic cancer, patient responses to this radical
treatment are complex and need to be studied further.63 The primary purpose of our study was to
examine factors associated with treatment refusal of surgery and chemotherapy by NSCLC
patients.

Materials and Methods
Study Population, Design, and Data Source
Our study utilized the National Cancer Database (NCDB), a joint project of the American
Cancer Society (ACS) and the Commission on Cancer (CoC) of the American College of
Surgeons (ACoS). It serves as a nationwide cancer surveillance program that captures
approximately 70% of newly diagnosed cancers in the US.107,112
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In this cross-sectional study, all patients diagnosed with NSCLC between 2003 and 2012
were eligible for inclusion in the analysis, with 1,237,129 NSCLC cases recorded in the database.
We used the following eligibility criteria for sample selection: (1) diagnosed with a primary
invasive lung cancer and (2) diagnosed at CoC-accredited facilities and received all/part of the
treatment from CoC facilities. Figure 3.1 shows a flow chart of sample selection, with a final
sample size of 884,817 after the application of inclusion criteria.
Exposures and Outcomes
We included information on patient demographic and clinical characteristics as predictor
variables and examined refusal of recommended treatment as the study outcome. The NCDB
defines treatment refusal as a condition when patients refuse the standard therapy recommended
by their physician. Patient responses were recorded for each therapy, e.g., surgery and
chemotherapy, separately.111 If patients refused the recommended therapy, they were included in
the refusal group; if there was no contraindication recorded, all others were included in the
acceptance group. It should be noted that the NCDB does not record information regarding
patients’ follow-up for a second opinion. The standard quality measures for evaluation of lung
cancer directed-therapy in NSCLC used by the Veteran Health Administration include
recommendations of curative surgery for stages I and II and recommendations for chemotherapy
for stages III and IV.132 Therefore, we focused the treatment refusal analysis on these therapies
for these respective stages.
Statistical Analysis
We compared demographic and clinical characteristics of patients who refused to those
who accepted the recommended therapy. A bivariate analysis was conducted to examine potential
association of predictor variables with an outcome, i.e., refusal of surgery or refusal of
chemotherapy. Predictor variables that showed statistically significant association with outcome
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in the bivariate analysis or variables that are important from a clinical or biological standpoint
were included in multivariable analyses.
Predictors included in multivariable logistic regression analysis were: age at diagnosis,
gender, race, primary payer, residence category, histologic type, tumor size, comorbid conditions,
and facility type. The dataset was partitioned into three parts according to cancer stage: refusal of
surgery for stages I and II, refusal of chemotherapy for stage III, and for refusal of chemotherapy
for stage IV. All tests were two-sided, with a p-value < 0.05 considered statistically significant.
All analyses were conducted using the SAS software version 9.4 (SAS Institute; Cary, NC).
Confidentiality and Ethics
The data used in the present study were derived from a de-identified NCDB file. Results
reported in this study are in compliance with the privacy requirements of the Health Insurance
Portability and Accountability Act of 1996. The ACS and CoC have not verified, and neither is
responsible for the analytic and statistical methods utilized in this study. The statements made in
the discussion and the conclusions drawn from these data are solely those of the investigators.
Given that it uses existing and de-identified data, this study has been classified as exempt by the
Institutional Review Board of University of Nebraska Medical Center.

Results
Demographic and clinical characteristics of NSCLC patients are presented in Table 4.1.
The cohort included predominantly White patients (85%). There was a male preponderance
(53%), and 51% of patients were diagnosed between 50 and 70 years of age. The majority of
patients were covered by Medicare (57%) and private insurance (29%), while approximately 4%
were uninsured. More than half of patients were diagnosed with advanced stages, specifically
stage III (23%) and stage IV (40%).
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Of the 257,811 patients diagnosed with stages I and II, surgery was recommended for
73%. There were 199,166 patients diagnosed with stage III and 354,892 diagnosed with stage IV.
Chemotherapy was recommended for 69% and 57% of these patients, respectively (data not
shown). Figure 3.2 shows a higher proportion of treatment refusal as the stage increased; the
proportion of patients who refused treatments ranged from 2–9%.
Among patients diagnosed with stages I and II, and for whom surgery was recommended,
a higher percentage of older-onset patients (age > 70 years) refused treatment (71%) (Table 4.2).
A higher proportion of those who were covered by private insurance agreed to undergo surgery,
while a lower proportion of patients with Medicare agreed (p < 0.001). Interestingly, patients with
no comorbid conditions were more likely to refuse surgery. Patients without comorbidity were
more likely to agree to the recommended chemotherapy than those with comorbid conditions (p <
0.001).
Results of the multivariable analysis are presented in Table 4.3. Compared with
intermediate-onset patients (age 50–70 years), patients diagnosed at younger-onset (age < 50
years) were less likely to refuse treatment, while older-onset patients were more likely to refuse
treatment. The adjusted odds ratio (AOR) was 0.37 for refusal of surgery (95% CI: 0.28–0.49)
and AOR = 0.58 for refusal of chemotherapy for stage III (95% CI: 0.49–0.68). Uninsured
patients were more likely to refuse treatment than those with private insurance, with the AOR
being 2.47 for refusal of surgery (95% CI: 1.89–3.20) and AOR = 2.56 for refusal of
chemotherapy for stage III (95% CI: 2.19–2.98) and AOR = 2.50 for stage IV (95% CI: 2.27–
2.75).
Patients with comorbid conditions were less likely to refuse surgery, but more likely to
refuse chemotherapy. In addition, we found that patients treated at academic facilities were less
likely to refuse surgery (AOR = 0.45; 95% CI: 0.40–0.50) or chemotherapy (for stage III AOR =
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0.78; 95% CI: 0.72–0.86; and for stage IV AOR = 0.68; 95% CI: 0.64–0.73). Potential interaction
of race with insurance status was examined, and we found no significant association.

Discussion
This study is one of a very limited number of studies that have examined the association
of various factors related to treatment refusal among NSCLC patients. The analysis of refusal of
surgery and chemotherapy in this study delineate comprehensive care of patients with early and
advanced stages of lung cancer. Using similar category of treatment refusal, analyses of 11 cancer
sites, including lung cancer by Ward et al., suggested that surgery and chemotherapy were the
most commonly refused treatment modality.95 Our results showed that the proportion of treatment
refusal ranged from 2–9%. Use of a national facility-based cancer registry enabled us to analyze
more clinical data than previous studies.
We found that older-onset patients were three times more likely to refuse surgery or
chemotherapy than intermediate-onset patients. Similar findings were reported in studies of earlystage NSCLC patients.97,99,132 De Rijke et al. reported that older age (75+ years) was the most
important factor for patients not to receive standard treatment.125 Among the older-onset patients,
treatment refusal was frequently affected by fear of toxicity or treatment side effects, treatment
duration, and patient beliefs about the effectiveness of the treatment offered.92,93,99,150 A
systematic review of patients’ decisions in cancer treatment showed that older adults might
choose the quality of life over survival prolongation.93 In addition, older patients might have other
diseases in addition to cancer that could affect treatment tolerability, effectiveness, and life
expectancy.93,99 Differences in priorities and comorbidities among older patients influence their
decision to decline treatment offered.
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Findings on the effect of gender have been mixed. Our analysis found no difference in
surgical refusal between males and females with early-stage cancer. Similar findings have been
reported in previous studies.99,131 However, among patients diagnosed with stage III and stage IV
and recommended chemotherapy, we observed that women were more likely to refuse treatment
than men. Findings from a multisite cohort study among patients with advanced cancer also
reported that women were less likely than men to agree to aggressive end-of-life treatments.142
Explanations of the differences among patients with advanced cancer stages seem related to the
individual patient’s view of life, their values, and personal judgment. Women appeared more
likely to understand that they had an incurable disease, which influenced their decision to forgo
the treatment.100 A different study among severely ill patients, including some cancer patients,
suggested that women were more likely to believe that medical recommendations were only for
comfort care rather than intended to prolong life.101
The American Society of Clinical Oncology has highlighted the issue of significant
inequities in cancer care related to insurance status.145 Previous studies have reported that lung
cancer was among cancers with a high prevalence of uninsured cases in the US.103,144 Our study
found that 55,465 patients were on Medicaid and 33,254 patients were uninsured. Our analysis
further revealed that patients without insurance and those on Medicaid were 2–3 times more
likely to refuse surgery or chemotherapy than those with private insurance.
A national study of pathology and patterns of NSCLC care suggested that
recommendation for surgery was determined more by cancer stage and patients’ age than by
comorbidity.151 Conversely, other studies found that comorbid conditions were associated with a
higher surgical refusal.99,132,152 Our study found that patients without comorbidity were more
likely to refuse surgery than those with comorbidity. It is possible that patients without
comorbidity believe they are healthier and, therefore, choose to seek a second opinion before
deciding to accept recommended surgery.153 because surgery is considered a radical treatment, the
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decision to have it might be affected by other nonclinical factors such as access to medical care,
patient–physician interactions, and patient perception of the necessity of surgery.99,132,153,154 As
reported by Bradley et al., the length of stay and cost of inpatient care influence patients’
decisions concerning whether or not to accept surgery, especially for those who are uninsured and
underinsured.155 The influence of these factors on patients’ decisions to decline recommended
treatment requires further investigation in future studies.
Finally, previous studies in lung cancer have reported that due to problems in accessing
health facilities, those living in rural areas were more likely to refuse the treatment options than
patients residing in urban area.132,154 However, our study did not find this association, possibly
due to a small proportion of patients coming from rural areas.
A few limitations of the study should be considered for interpretation of the study
findings. About 20–25% of newly diagnosed cancer patients are treated at non-CoC facilities that
are not part of the NCDB data.103 However, Mettlin et al. reported marginal differences in patient
and treatment characteristics between Surveillance, Epidemiology and End Results (SEER) and
the NCDB.148 The wide coverage and diverse nature of the CoC facilities, as well as the small
differences, contribute to our confidence in the generalizability of the study findings. Another
limitation of the NCDB data was that factors that may contribute to treatment refusal, such as
patient’s social support, patient–physician interactions, and level and type of psychological
stressors were not measured. These important factors need to be examined further in future
studies.

Conclusions
Multiple patient and system-related factors, such as older age at diagnosis, comorbid
conditions, and uninsured status, were associated with higher treatment refusal. Consideration of
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these factors is essential to develop strategies for patient education and patient–provider
communication. Further investigations are needed to identify the beneficial treatments that cover
both clinical and patient aspects.
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Table 4. 1 Patient Demographic and Clinical Characteristics
Characteristics
Age at diagnosis (years)
< 50
50–70
> 70
Gender
Male
Female
Race
White
Black
Others/unknown
Primary Payer
Uninsured
Private insurance
Medicaid
Medicare
Other government
Unknown
Median Income Quartiles
2008–2012
< $ 38,000
$ 38,000–$ 47,999
$ 48,000–$ 62,999
$ 63,000 +
Unknown
Category Residence
Metro counties
Urban counties
Rural counties
Unknown
AJCC analytic stage
Stage I
Stage II
Stage III
Stage IV
Missing+
+Missing

Total NSCLC cases
N = 884,817
%
57,674
449,339
377,804

6.5
50.8
42.7

471,891
412,926

53.3
46.7

750,676
101,436
32,705

84.8
11.5
3.7

33,254
255,058
55,465
506,989
11,278
22,773

3.8
28.8
6.3
57.3
1.3
2.6

185,912
222,090
226,808
224,291
25,716

21.0
25.1
25.6
25.4
2.9

691,638
135,567
18,489
39,123

78.2
15.3
2.1
4.4

193,098
64,713
199,166
354,892
72,948

21.8
7.3
22.5
40.1
8.2

include AJCC staging not applicable/unknown

Characteristics
Tumor size (cm)
<3
3–7
>7
Tumor involvement at lung
Unknown
Charlson/Deyo Comorbid
Conditions (CDCC)$
No comorbid condition
Score 1
Score 2
Histology
Non-small cell carcinoma
Squamous cell carcinoma
Adenocarcinoma
Large cell carcinoma
Others

Total NSCLC cases
N = 884,817
%
285,149
309,134
85,714
1,591
203,229

32.2
34.9
9.7
0.2
23.0

524,606
248,723
111,488

59.3
28.1
12.6

150,323
214,879
368,423
30,363
120,829

17.0
24.3
41.6
3.4
13.7

106,766
499,651
277,276
1,124

12.1
56.5
31.3
0.1

167,109
126,556
108,457
80,520

18.9
14.3
12.3
9.1

196,902

22.3

196,022

22.2

9,251

1.1

CoC Facility
Community
Comprehensive Community
Academic/Research
Other cancer programs
First course treatment
Surgery
Radiotherapy
Chemotherapy
Surgery and chemo and/or
radiotherapy
Chemotherapy and
radiotherapy
No surgical, chemo or
radiotherapy received
Unknown
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Table 4. 2 Characteristics of Patients Who Accepted vs. Refused Recommended Treatment: Surgery for Stage I-II, and
Chemotherapy for Stage III-IV

Characteristics
Age at diagnosis (years)
< 50
50–70
> 70
Gender
Male
Female
Race
White
Black
Others/unknown
Primary Payer
Uninsured
Private insurance
Medicaid
Medicare
Other government
Unknown
Median Income Quartiles
2008–2012
< $ 38,000
$ 38,000–$ 47,999
$ 48,000–$ 62,999
$ 63,000 +
Unknown
Category Residence
Metro counties
Urban counties
Rural counties
Unknown

Stage I and II –
recommended surgery
Accepted
Refused
n = 181,721
%
n = 4,313
%

p value

Stage III and IV –
recommended chemotherapy
Accepted
Refused
n = 300,519
%
n = 27,452

p value
%

10,540
100,293
70,888

5.8
55.2
39.0

60
1,174
3,079

1.4
27.2
71.4

< 0.001

28,982
183,158
88,379

9.6
61.0
29.4

886
10,207
16,359

3.2
37.2
59.6

< 0.001

88,514
93,207

48.7
51.3

2,089
2,224

48.4
51.6

0.722

167,820
132,699

55.8
44.2

13,779
13,673

50.2
49.8

< 0.001

160,718
14,821
6,182

88.4
8.2
3.4

3,569
575
169

82.8
13.3
3.9

< 0.001

251,503
37,138
11,878

83.7
12.4
4.0

23,518
2,899
1,035

85.7
10.6
3.8

< 0.001

3,498
60,227
7,737
104,808
1,632
3,819

1.9
33.1
4.3
57.7
0.9
2.1

76
527
211
3,388
45
66

1.8
12.2
4.9
78.6
1.0
1.5

< 0.001

13,659
110,836
22,961
141,223
4,058
7,782

4.6
36.9
7.6
47.0
1.4
2.6

1,237
4,521
1,935
19,015
271
473

4.5
16.5
7.1
69.3
1.0
1.7

< 0.001

33,416
44,258
47,772
52,117
4,158

18.4
24.4
26.3
28.7
2.3

999
1,120
1,110
1,016
68

23.2
26.0
25.7
23.6
1.6

< 0.001

60,778
74,523
77,712
78,092
9,414

20.2
24.8
25.9
26.0
3.1

6,194
7,279
6,970
6,325
684

22.6
26.5
25.4
23.0
2.5

< 0.001

142,594
28,246
3,722
7,159

78.5
15.5
2.1
3.9

3,406
690
76
141

79.0
16.0
1.8
3.3

0.066

233,671
46,515
6,463
13,870

77.8
15.5
2.2
4.6

21,470
4,359
594
1,029

78.2
15.9
2.2
3.8

< 0.001
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Characteristics
Tumor size (cm)
<3
3–7
>7
Tumor involvement at lung
Unknown
CDCC
No comorbid condition
Score 1
Score 2
Histology
Non-small cell carcinoma
Squamous cell carcinoma
Adenocarcinoma
Large cell carcinoma
Others
CoC Facility
Community
Comprehensive
Community
Academic/Research
Other cancer programs

Stage I and II –
recommended surgery
Accepted
Refused
n = 181,721
%
n = 4,313
%

p value

Stage III and IV –
recommended chemotherapy
Accepted
Refused
n = 300,519
%
n = 27,452

p value
%

112,687
58,503
8,325
9
2,197

62.0
32.2
4.6
0.0
1.2

2,202
1,629
186
0
296

51.1
37.8
4.3
0.0
6.9

< 0.001

67,966
116,028
37,415
683
78,427

22.6
38.6
12.5
0.2
26.1

5,737
10,614
3,533
92
7,476

20.9
38.7
12.9
0.3
27.2

< 0.001

93,470
64,179
24,072

51.4
35.3
13.3

2,477
1,185
651

57.4
27.5
15.1

< 0.001

202,250
72,208
26,061

67.3
24.0
8.7

14,430
8,467
4,555

52.6
30.8
16.6

< 0.001

8,439
53,797
97,382
6,148
15,955

4.6
29.6
53.6
3.4
8.8

660
1,119
1,213
78
1,243

15.3
25.9
28.1
1.8
28.8

< 0.001

65,275
69,056
133,709
11,427
21,052

21.7
23.0
44.5
3.8
7.0

4,833
5,998
9,722
862
6,037

17.6
21.9
35.4
3.1
22.0

< 0.001

15,050
101,367

8.3
55.8

659
2,474

15.3
57.4

< 0.001

37,828
166,419

12.6
55.4

4,226
16,686

15.4
60.8

< 0.001

64,942
362

35.7
0.2

1,173
7

27.2
0.2

95,898
374

31.9
0.1

6,495
45

23.7
0.2
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Table 4. 3 Multivariable Logistic Regression of Factors Associated with Treatment Refusal

Characteristics
Age at diagnosis (years)
50–70
< 50
> 70
Gender
Male
Female
Race
White
Black
Others/unknown
Primary Payer
Private insurance
No insurance
Medicaid
Medicare
Other government
Category Residence
Metro counties
Urban counties
Rural counties
Histology
Adenocarcinoma
Non-small cell carcinoma
Squamous cell carcinoma
Large cell carcinoma
Others
Tumor size (cm)
<3
3–7
>7

Refusal of Surgery
(stage I and II)
AOR
95% CI
p < 0.001
Ref
0.37
0.28 - 0.49
3.42
3.15 - 3.71
p = 0.056
Ref
1.07
1.00 - 1.14
p < 0.001
Ref
2.25
2.04 - 2.49
1.42
1.19 - 1.68
p < 0.001
Ref
2.47
1.89 - 3.20
3.09
2.59 - 3.69
2.04
1.84 - 2.27
2.92
2.10 - 4.04
p = 0.249
Ref
0.99
0.90 - 1.08
0.81
0.63 - 1.04
p < 0.001
Ref
6.16
5.54 - 6.85
1.43
1.31 - 1.57
1.08
0.84 - 1.37
7.44
6.82 - 8.12
p < 0.001
Ref
1.33
1.24 - 1.42
1.19
1.02 - 1.40

Refusal of Chemotherapy
(stage III)
AOR
95% CI
p < 0.001
Ref
0.58 0.49 - 0.68
3.16 2.97 - 3.37
p < 0.001
Ref
1.31 1.24 - 1.38
p = 0.019
Ref
1.06 0.98 - 1.15
1.20 1.04 - 1.38
p < 0.001
Ref
2.56 2.19 - 2.98
2.26 2.00 - 2.56
1.75 1.61 - 1.89
1.55 1.21 - 1.98
p = 0.797
Ref
0.98 0.91 - 1.05
0.96 0.81 - 1.14
p < 0.001
Ref
1.12 1.04 - 1.21
1.22 1.14 - 1.31
0.96 0.82 - 1.12
3.90 3.59 - 4.23
p = 0.015
Ref
1.06 1.00 - 1.13
1.12 1.03 - 1.21

Refusal of Chemotherapy
(stage IV)
AOR
95% CI
p < 0.001
Ref
0.58 0.52 - 0.64
2.68 2.56 - 2.81
p < 0.001
Ref
1.25 1.20 - 1.30
p = 0.192
Ref
0.99 0.93 - 1.05
1.09 0.99 - 1.21
p < 0.001
Ref
2.50 2.27 - 2.75
2.12 1.96 - 2.31
1.69 1.60 - 1.79
1.48 1.20 - 1.82
p = 0.455
Ref
0.98 0.93 - 1.03
0.94 0.82 - 1.07
p < 0.001
Ref
1.05 1.00 - 1.11
1.21 1.15 - 1.28
1.18 1.06 - 1.32
4.16 3.95 - 4.39
p < 0.001
Ref
1.06 1.01 - 1.11
1.24 1.17 - 1.31
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Characteristics
Tumor involvement at the lung
CDCC
No comorbid
Score 1
Score 2
Facility
Community
Comprehensive Community
Academic/Research
Other cancer programs
AOR = Adjusted Odds Ratio

Refusal of Surgery
(stage I and II)
AOR
95% CI
< 0.001 < 0.001 - ∞
p < 0.001
Ref
0.64
0.59 - 0.69
0.87
0.79 - 0.96
p < 0.001
Ref
0.57
0.52 - 0.63
0.45
0.40 - 0.50
0.75
0.35 - 1.62
CI = Confidence Interval

Refusal of Chemotherapy
(stage III)
AOR
95% CI
1.90 0.93 - 3.89
p < 0.001
Ref
1.42 1.34 - 1.51
1.94 1.81 - 2.09
p < 0.001
Ref
0.97 0.90 - 1.05
0.78 0.72 - 0.86
1.18 0.62 - 2.26

Refusal of Chemotherapy
(stage IV)
AOR
95% CI
1.53 1.19 - 1.96
p < 0.001
Ref
1.48 1.42 - 1.55
1.99 1.88 - 2.11
p < 0.001
Ref
0.91 0.86 - 0.96
0.68 0.64 - 0.73
1.04 0.65 - 1.66
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Figure 4. 1 Sample Selection

Non-small cell lung cancer diagnosed between 2003–2012 in NCDB (N = 1,237,129)

Excluded from sample selection:
-

Multiple cancer diagnoses and lung cancer was not the primary
cancer (n = 266,396)
Non-invasive lung tumor (n = 1,542)
Diagnosed but did not receive any treatment from the reporting
CoC facility (n = 108,822)

Sample size used in the analysis (n = 884,817)
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Figure 4. 2 Treatment Recommendations and Patient Response

Chemotherapy
for stage IV

84.0
8.9

Chemotherapy
for stage III

7.0

89.0
6.3 4.8

Surgery
for stage II

90.4
2.0 7.6

Surgery
for stage I

91.1
2.2 6.7
0.0

25.0

50.0

75.0

Percentage
Received therapy

Refused therapy

Contraindication to therapy

100.0
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CHAPTER 5
DISCUSSION AND CONCLUSIONS

Lung cancer is a major cause of cancer morbidity and mortality in the US. The estimation
made in 2018 suggests that lung cancer diagnosis is the second most commonly diagnosed cancer
in both genders.11 Although many improvements in diagnosis and treatments have been
achieved,5,11,13 the number of deaths due to lung cancer is still high. For both genders, lung cancer
is causing 25% of all cancer-related deaths.11,12 Recent report indicate the relative five-year
survival rate of lung cancer is only 18%.11 Because of the great burden of lung cancer,
investigating and examining factors associated with survival are essential to suggest areas of
improvement in lung cancer care.
This dissertation focused on investigating factors associated with the survival of lung
cancer patients through three specific aims. First, we examined the survival of NSCLC patients
and analyzed factors associated with the survival. Second, we investigated the effect of treatment
refusal on the survival of SCLC patients and factors associated with treatment refusal by patients.
Lastly, we investigated factors associated with treatment refusal of NSCLC patients.

Study Findings and Its Relevance to Literature
Earlier findings suggest that individuals with different age at diagnosis of lung cancer
have different characteristics, such as cancer stage, type of tumor, and genetic susceptibility.44,45,47
Our results included in Chapter 2 demonstrate that a higher proportion of patients among the
younger-onset patients were diagnosed at advanced stages, had a positive family history of
cancer, were current smokers, and had adenocarcinoma histology than the older-onset cases.
Other studies have observed similar findings on characteristics of the younger-onset lung cancer
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patients from the analyses of population and facility-based data.45,47,79 Patients diagnosed with
lung cancer at different age have different characteristics.44,45,47
Studies reported that many of the younger-onset lung cancer patients were typically
symptomatic and diagnosed at an advanced stage.42,48,86 One explanation may be that a younger
patient is less likely to think that he or she could have developed lung cancer at a younger than
typical age. These young people perhaps pay less attention to the respiratory symptoms and
present later to their providers. In addition, a general practitioner may suspect less about a
younger patient to have lung cancer than an older patient with similar symptoms. This condition
may delay the health provider in ordering diagnostic tests to detect lung cancer.
Previous studies also indicate that the late diagnosis among young lung cancer patients
was due to issues with not having insurance, being underinsured, and having limited access to
cancer care.103,105,106 It is also possible that because of the social perception that lung cancer is a
self-inflicted disease, it may hinder young patients to take a lung cancer screening. Consequently,
these young patients ended up being diagnosed with lung cancer at an advanced stage. Lung
cancer is mostly known as a disease of older people, but the literature suggests that a substantial
number of lung cancer cases occur before the age of 50 years.12,17,41,42 Studies defined this group
of patients as younger-onset lung cancer cases.17,31,34 The observed proportion of younger-onset
lung cancer in the databases that we used, the VACCR and the NCDB data, were 2.4% and 6.5%,
respectively. Those proportions we observed were relatively similar to previous studies.47,79
The survival of lung cancer patients has been examined in previous studies and results
suggest multiple factors were associated with survival including age at diagnosis.45,47,48,79
However, the direction of the association between age at diagnosis and patients’ survival has been
inconclusive. Among the veterans population, our results show that the overall five-year survival
of younger-onset patients was 5.6% compared with 3.0% of older-onset patients (> 70 years).
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These results corroborate findings from earlier studies suggesting a higher survival among
younger-onset patients than older-onset patients.45,47,79
While multiple factors were associated with overall survival, our results indicate that age
at diagnosis and cancer stage were factors that strongly influenced patients’ survival. Notable
differences in clinical and statistical results that suggest a better five-year survival among the
younger-onset were shown among early-stage (I and II) patients, whereas among advanced stage
(III and IV) patients, only a marginal difference in survival was seen between the younger- and
older-onset. It is likely that the disease aggressiveness at advanced stages of NSCLC lowers the
overall survival of both younger-and older-onset patients.
Previous studies also suggest that the fewer comorbidities and a better performance status
among younger-onset patients were contributed to a better survival.41,45,46 Younger patients are
typically healthier; thus, physicians were more likely to recommend them for an aggressive
treatment, including surgery than older patients. In addition, it is likely that comorbidities
associated with increasing age lead to lower survival in the older patients. Unfortunately, the
VACCR database that we analyzed does not capture clinical information such as comorbid
conditions and patient performance status. The availability of more comprehensive information
will enable us to better explain the higher survival among younger-onset patients.
Treatment decline was another factor suggested as being directly associated with cancerrelated deaths.63,104 However, that information is still not convincing enough for lung cancer
patients to take the recommended treatment. Of all lung cancer cases, the SCLC patients are well
known to have the least five-year survival rates. A recent report indicates the five-year survival
rate of SCLC was less than 7%.12
In Chapter 3, we present our results on survival analyses according to typical
recommended therapies for patients diagnosed at different cancer stages for SCLC: LS-SCLC and
ES-SCLC. The common recommended therapy for LS-SCLC patients is concurrent
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chemoradiotherapy; whereas, ES-SCLC cases are predominantly treated with
chemotherapy.55,126,128 The results of our analyses among SCLC patients suggest that patients who
received the recommended treatment had a significantly higher survival than those who declined
the treatment, both in LS-SCLC and ES-SCLC. The overall median survival of SCLC patients
was 9.4 months. Our results show that among LS-SCLC patients who were recommended
chemoradiotherapy, the median survival of patients who refused and received the treatment was 3
and 18 months, respectively. For ES-SCLC patients, the median survival of those who refused
chemotherapy was 1 month compared with 7.5 months of patients who received therapy.
Our findings were consistent with previous studies that suggested better survival rates
among SCLC patients who received treatment than those who declined.136,147 In multivariable
analyses using the Cox PH regression, our results show that younger age, female gender, private
insurance, no comorbid conditions, and acceptance of cancer treatment were associated with
lower risk of mortality. Of those factors, treatment refusal demonstrates a profound effect. Of LSSCLC patients who were recommended chemoradiotherapy, those who declined treatment had
five times higher risk of mortality than those who received treatment. Similarly, among ES-SCLC
patients who were recommended chemotherapy, patients who refused treatment had about four
times higher risk of mortality than those who received treatment. A better survival may have
resulted from a combination of multiple factors, however, it is likely that acceptance of treatment
may increase patient life expectancy. Nevertheless, we have to acknowledge that the existence of
barriers in the use of optimal lung cancer care is a complex condition. Many factors may play a
role in the final decision for lung cancer care including diagnostic tests, patient preference,
cultural aspects, and provider judgment.
Studies have reported a higher rate in underuse of treatment modalities among lung
cancer patients than other cancers.63,95,97 Treatment refusal is an important reason for
underutilization of recommended treatment among lung cancer patients. However, evidence of
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factors associated with treatment refusal among lung cancer patients are lacking. Our results
showed factors that associated with treatment refusal among the early and advanced stages lung
cancer patients and those factors can suggest areas of improvement in lung cancer care.
In Chapter 3, our results show that a majority of first-course treatments received by
SCLC patients were according to the clinical practice guidelines. The overall refusal of
recommended chemoradiotherapy among LS-SCLC patients was 1.34% and the refusal of
chemotherapy among ES-SCLC patients was 4.7%. Over 10 years of data, we observed an
increase in proportions of treatment refusal among SCLC cases, especially ES-SCLC patients.
With approximately 75% of SCLC cases diagnosed with ES-SCLC, issues associated with
treatment refusal deserve attention in regard to the lethality of this type of cancer.
For NSCLC, the current guidelines indicate surgery as the primary treatment for operable
early-stage cancer (stages I and II).156 For advanced stage cancer, treatment options may include a
combination of chemotherapy, palliative radiation, and targeted therapy.13,52 The results presented
in Chapter 4 suggest that 2% to 9% of NSCLC patients refused the recommended treatment and a
higher proportion of refusal was seen among patients with advanced stages. Furthermore, we
observed multiple patient and system-related factors that were associated with patient decision to
refuse recommended treatment. Of those factors, older age at diagnosis, female gender, comorbid
conditions, and uninsured status were strongly associated with higher treatment refusal. We could
not explore more about the aforementioned factors in this study as the variables in the database
are limited; however, our literature review may suggest possible reasons for the factors we
observed. Another limitation, because the data do not have follow up information for treatment
refusal, we cannot assessed if the patient made changes in their decision.
Despite the fact that previous studies have shown both older and younger patients
respond just as well to combined modality therapy,89,90 older-onset lung cancer patients were
more likely to refuse treatment than younger patients. Studies suggest that factors that may
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support young patients to agree to cancer treatment were their overall health status and less
comorbid conditions.135 In contrast, older-onset patients have increased concerns regarding their
tolerability to treatment, duration and effectiveness of treatment, and comorbid conditions that
eventually influenced their decision to decline the offered treatment.93,135 Other studies also
suggest that older-onset patients might not see their chance to be curable, thus they opt out of the
recommended treatment.93 It has also been reported that older patients may not receive enough
information about treatment options and its benefits that discourage them from taking
treatment.157,158 Statistics have been shown demographic shift toward an older population and
with majority of lung cancer cases diagnosed at older age, it may explain the increase pattern of
treatment refusal.
Results of our analyses suggest that women, especially those with advanced stage lung
cancer, were more likely to refuse the recommended therapies. Differences according to gender
may be related to patients’ perceptions of cancer care.100,101 Previous studies suggest that women
with advanced stages cancer tend to refuse the treatment options due to nonclinical reasons such
as they prefer the quality of life more than prolonging life142 and tend to plan for other things in
their end-of-life rather than to complete cancer treatment series.100,143 In addition, earlier studies
reported that women were clinically more vulnerable to treatment toxicities than men.100,143
Understanding concerns associated with treatment refusal among women is important in regard to
incidence rates of lung cancer among women.12
From the analyses of NCDB data on treatment refusal, we observed an interesting finding
that patients without comorbidity were more likely to decline surgery than those with comorbidity
among early-stage cancer. We cannot further analyze the comorbid conditions that were
associated with the refusal because the database only included information about comorbidity
scores. Literature suggests that patients were considering surgery as a radical treatment, and their
decision to take it was strongly affected by other factors such as access to medical care, patient–
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physician interactions, and patient perception of the necessity of surgery.99,132,153,154 A qualitative
study by George et al. suggested that following the surgical recommendation, lung cancer patients
usually searched for a second opinion before making a plan to take the option.153 The length of
stay and cost of inpatient care associated with surgery were some of the factors that concerned
patients, particularly for patients without an insurance plan.155
In regard to insurance, our results suggest that uninsured and Medicaid patients were two
to three times more likely to refuse either surgery or chemotherapy than those with private
insurance. Similar findings to our results have been reported by previous studies.159 Concerns
about treatment cost and limited insurance coverage were indicated by different studies resulting
in a lack of diagnostic and therapeutic cancer care received by uninsured and underinsured
patients.103,160 The issue for non-optimal cancer care associated with insurance status has caused a
substantial concern that the American Society of Clinical Oncology highlighted it as the issue of
significant inequities in cancer care.145 To achieve equity in health care, approaches to remove the
barriers such as access to lung cancer screening and treatment need to be addressed.

Implication of Current Research
Findings from this dissertation emphasize the importance of understanding factors
associated with survival and patient decision for lung cancer treatment. Our focus on age at
diagnosis would not only explain the influences over disease prognosis but also offer
explanations related to the patient’s view of life, their values, and personal judgment.
Our results demonstrated that more of the younger-onset group patients were diagnosed
at advanced stages. The results may indicate issues on access to lung cancer screening, especially
among young patients. Improvements, such as providing a better access for lung cancer screening
among young patients with symptoms, may prevent cases being diagnosed at an advanced stage.
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In addition, a higher survival observed among younger-onset patients could be a point of
interest for health providers and health system. The possibilities that younger-onset patients have
better health performance, fewer comorbidities, and higher acceptance to treatment may enable
health providers to recommend more diverse treatment options. Identifying and treating youngeronset lung cancer patients may be a point to improve the survival and to reduce mortality rates of
lung cancer.
To improve patients’ survival in relation to treatment refusal, our results in Chapters 3
and 4 may suggest points to enhance in patient education and patient–provider communication.
Our data indicate that older-onset patients, having comorbid conditions, and being uninsured were
more likely to refuse recommended treatment. Thus, it is important to inform patients with these
characteristics about treatment options and its benefits including palliative treatment that essential
for patients in making their decision. Although the majority of patients with advanced stage lung
cancer cannot be cured, they can still make plans of their interest in end-of-life. Options for less
toxic treatment regimens or palliative care that may improve patient quality of life should work
better than having no treatment.

Suggested Future Research
Findings presented in this dissertation are expected to add more information to the
existing body of literature on lung cancer research. With the higher burden of morbidity and
mortality of lung cancer, more research should be directed to address gaps in identifying and
treating patients. We have included some suggestions that may be focused in future studies.
The results indicate that younger-onset patients were more likely diagnosed at advanced
stages. It is possible because the lack of attention to their health caused these younger people to
present later at their health provider. However, earlier studies suggest that genetic susceptibility
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related to detoxifying reactive metabolites of tobacco smoke procarcinogens among young
patients with genetic polymorphisms of glutathione S-transferases exposed them to a higher risk
of developing cancer.34 Different studies indicate that lung cancer patients diagnosed at less than
50 years of age have predisposing genetic factors.33,49,50 To better understand the risk for youngeronset lung cancer, future research should try to identify genetic features that are more prevalent
among the younger-onset than the older-onset. In addition, results also showed that younger-onset
patients presented more with adenocarcinoma histology and positive family history of cancer.
Further investigations into tumor molecular characteristics or genetic mutations are needed to
explain lung cancer at a younger age and potential targeted therapies.
In our discussion of factors associated with survival, databases that we used for this
dissertation do not include comprehensive information that may better explain the findings.
Further research should include factors such as types of comorbidities, patient performance status,
exposures from smoking, amount of smoking, and other environmental factors to present a more
comprehensive understanding on profound factors associated with the survival of lung cancer
patients.
The current research found that younger-onset lung cancer patients obtained the greatest
benefits of treatment because they are relatively eligible for aggressive treatment and are less
likely to refuse treatment in comparison to the older patients. Future research needs to evaluate
this further and see if improvement in survival could also be achieved by increasing awareness
about lung cancer risk factors and improving access to screening and treatment of lung cancer.
For the older-onset group, more work should see if by improving patient education and patient–
physician communication, more patients are taking the recommended treatment. In addition,
future studies should aim to identify the most beneficial treatment for lung cancer that addresses
both clinical and patient aspects.
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Conclusions
The results of this dissertation suggest that multiple factors were associated with patients’
survival including age at diagnosis and treatment refusal. The younger-onset patients had a better
survival and were less likely to refuse recommended treatments than the older-onset patients. Our
findings support the notion of better access for lung cancer screening, patient education, and
patient–provider communication, as well as genetic studies to improve the survival of lung cancer
patients.
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